Solid forms of gyrase inhibitor (R)-1-ethyl-3-[6-fluoro-5-[2-(1-hydroxy-1-methyl-ethyl)pyrimidin-5-yl]-7-(tetrahydrofuran-2-yl)-1H-benzimidazol-2-yl]urea

ABSTRACT

The present application is directed to solid forms of compounds of formula I: 
                         
and pharmaceutically acceptable salts thereof, that inhibit bacterial gyrase and/or Topo IV and pharmaceutical compositions comprising said compounds and salts. These compounds and salts are useful in treating bacterial infections.

CROSS REFERENCE TO RELATED APPLICATIONS

This application claims the benefit under 35 U.S.C. §119 of U.S.Provisional Patent Application Ser. No. 61/433,169 filed Jan. 14, 2011,the entire contents of which is incorporated herein by reference.

BACKGROUND OF THE APPLICATION

Bacterial resistance to antibiotics has long been recognized, and it istoday considered to be a serious worldwide health problem. As a resultof resistance, some bacterial infections are either difficult to treatwith antibiotics or even untreatable. This problem has become especiallyserious with the recent development of multiple drug resistance incertain strains of bacteria, such as Streptococcus pneumoniae (SP),Mycobacterium tuberculosis, and Enterococcus. The appearance ofvancomycin resistant enterococcus was particularly alarming becausevancomycin was formerly the only effective antibiotic for treating thisinfection, and had been considered for many infections to be the drug of“last resort”. While many other drug-resistant bacteria do not causelife-threatening disease, such as enterococci, there is the fear thatthe genes which induce resistance might spread to more deadly organismssuch as Staphylococcus aureus, where methicillin resistance is alreadyprevalent (De Clerq, et al., Current Opinion in Anti-infectiveInvestigational Drugs, 1999, 1, 1; Levy, “The Challenge of AntibioticResistance”, Scientific American, March, 1998).

Another concern is how quickly antibiotic resistance can spread. Forexample, until the 1960's SP was universally sensitive to penicillin,and in 1987 only 0.02% of the SP strains in the U.S. were resistant.However, by 1995 it was reported that SP resistance to penicillin wasabout seven percent and as high as 30% in some parts of the U.S. (Lewis,FDA Consumer magazine (September, 1995); Gershman in The MedicalReporter, 1997).

Hospitals, in particular, serve as centers for the formation andtransmission of drug-resistant organisms. Infections occurring inhospitals, known as nosocomial infections, are becoming an increasinglyserious problem. Of the two million Americans infected in hospitals eachyear, more than half of these infections resist at least one antibiotic.The Center for Disease Control reported that in 1992, over 13,000hospital patients died of bacterial infections that were resistant toantibiotic treatment (Lewis, “The Rise of Antibiotic-ResistantInfections”, FDA Consumer magazine, September 1995).

As a result of the need to combat drug-resistant bacteria and theincreasing failure of the available drugs, there has been a resurgentinterest in discovering new antibiotics. One attractive strategy fordeveloping new antibiotics is to inhibit DNA gyrase and/or topoisomeraseIV, bacterial enzymes necessary for DNA replication, and therefore,necessary for bacterial cell growth and division. Gyrase and/ortopoisomerase IV activity are also associated with events in DNAtranscription, repair and recombination.

Gyrase is one of the topoisomerases, a group of enzymes which catalyzethe interconversion of topological isomers of DNA (see generally,Kornberg and Baker, DNA Replication, 2d Ed., Chapter 12, 1992, W. H.Freeman and Co.; Drlica, Molecular Microbiology, 1992, 6, 425; Drlicaand Zhao, Microbiology and Molecular Biology Reviews, 1997, 61, pp.377-392). Gyrase itself controls DNA supercoiling and relievestopological stress that occurs when the DNA strands of a parental duplexare untwisted during the replication process. Gyrase also catalyzes theconversion of relaxed, closed circular duplex DNA to a negativelysuperhelical form which is more favorable for recombination. Themechanism of the supercoiling reaction involves the wrapping of gyrasearound a region of the DNA, double strand breaking in that region,passing a second region of the DNA through the break, and rejoining thebroken strands. Such a cleavage mechanism is characteristic of a type IItopoisomerase. The supercoiling reaction is driven by the binding of ATPto gyrase. The ATP is then hydrolyzed during the reaction. This ATPbinding and subsequent hydrolysis cause conformational changes in theDNA-bound gyrase that are necessary for its activity. It has also beenfound that the level of DNA supercoiling (or relaxation) is dependent onthe ATP/ADP ratio. In the absence of ATP, gyrase is only capable ofrelaxing supercoiled DNA.

Bacterial DNA gyrase is a 400 kilodalton protein tetramer consisting oftwo A (GyrA) and two B subunits (GyrB). Binding and cleavage of the DNAis associated with GyrA, whereas ATP is bound and hydrolyzed by the GyrBprotein. GyrB consists of an amino-terminal domain which has the ATPaseactivity, and a carboxy-terminal domain which interacts with GyrA andDNA. By contrast, eukaryotic type II topoisomerases are homodimers thatcan relax negative and positive supercoils, but cannot introducenegative supercoils. Ideally, an antibiotic based on the inhibition ofbacterial DNA gyrase and/or topoisomerase IV would be selective for thisenzyme and be relatively inactive against the eukaryotic type IItopoisomerases.

Topoisomerase IV primarily resolves linked chromosome dimers at theconclusion of DNA replication.

The widely-used quinolone antibiotics inhibit bacterial DNA gyrase(GyrA) and/or Topoisomerase IV (ParC). Examples of the quinolonesinclude the early compounds such as nalidixic acid and oxolinic acid, aswell as the later, more potent fluoroquinolones such as norfloxacin,ciprofloxacin, and trovafloxacin. These compounds bind to GyrA and/orParC and stabilize the cleaved complex, thus inhibiting overall gyrasefunction, leading to cell death. The fluoroquinolones inhibit thecatalytic subunits of gyrase (GyrA) and/or Topoisomerase IV (Par C) (seeDrlica and Zhao, Microbiology and Molecular Biology Reviews, 1997, 61,377-392). However, drug resistance has also been recognized as a problemfor this class of compounds (WHO Report, “Use of Quinolones in FoodAnimals and Potential Impact on Human Health”, 1998). With thequinolones, as with other classes of antibiotics, bacteria exposed toearlier compounds often quickly develop cross-resistance to more potentcompounds in the same class.

The associated subunits responsible for supplying the energy necessaryfor catalytic turnover/resetting of the enzymes via ATP hydrolysis areGyrB (gyrase) and ParE (topoisomerase IV), respectively (see, Champoux,J. J., Annu. Rev. Biochem., 2001, 70, pp. 369-413). Compounds thattarget these same ATP binding sites in the GyrB and ParE subunits wouldbe useful for treating various bacterial infections (see, Charifson etal., J. Med. Chem., 2008, 51, pp. 5243-5263).

There are fewer known inhibitors that bind to GyrB. Examples include thecoumarins, novobiocin and coumermycin Al, cyclothialidine, cinodine, andclerocidin. The coumarins have been shown to bind to GyrB very tightly.For example, novobiocin makes a network of hydrogen bonds with theprotein and several hydrophobic contacts. While novobiocin and ATP doappear to bind within the ATP binding site, there is minimal overlap inthe bound orientation of the two compounds. The overlapping portions arethe sugar unit of novobiocin and the ATP adenine (Maxwell, Trends inMicrobiology, 1997, 5, 102).

For coumarin-resistant bacteria, the most prevalent point mutation is ata surface arginine residue that binds to the carbonyl of the coumarinring (Arg136 in E. coli GyrB). While enzymes with this mutation showlower supercoiling and ATPase activity, they are also less sensitive toinhibition by coumarin drugs (Maxwell, Mol. Microbiol., 1993, 9, 681).

Despite being potent inhibitors of gyrase supercoiling, the coumarinshave not been widely used as antibiotics. They are generally notsuitable due to their low permeability in bacteria, eukaryotic toxicity,and poor water solubility (Maxwell, Trends in Microbiology, 1997, 5,102). It would be desirable to have a new, effective GyrB andParEinhibitor that overcomes these drawbacks and, preferably does notrely on binding to Arg136 for activity. Such an inhibitor would be anattractive antibiotic candidate, without a history of resistanceproblems that plague other classes of antibiotics.

As bacterial resistance to antibiotics has become an important publichealth problem, there is a continuing need to develop newer and morepotent antibiotics. More particularly, there is a need for antibioticsthat represent a new class of compounds not previously used to treatbacterial infection. Compounds that target the ATP binding sites in boththe GyrB (gyrase) and ParE (topoisomerase IV) subunits would be usefulfor treating various bacterial infections. Such compounds would beparticularly useful in treating nosocomial infections in hospitals wherethe formation and transmission of resistant bacteria are becomingincreasingly prevalent.

SUMMARY OF THE APPLICATION

The present application relates to solid forms of(R)-1-ethyl-3-[6-fluoro-5-[2-(1-hydroxy-1-methyl-ethyl)pyrimidin-5-yl]-7-(tetrahydrofuran-2-yl)-1H-benzimidazol-2-yl]urea(“the 6-fluoro benzimidazolyl urea compound”). In one embodiment, thepresent application provides solid Form I of the 6-fluoro benzimidazolylurea compound, which is characterized by an X-ray powder diffractionpattern (XPRD) comprising at least three approximate peak positions(degrees 2θ±0.2) when measured using Cu K_(α) radiation, selected fromthe group consisting of 9.3, 11.7, 12.1, 12.4, 14.5, 15.9, 16.3, 16.6,18.5, 19.4, 21.5, 22.3, 22.8, 23.8, 24.5, 25.7, 28.1, 28.4, 30.3, and33.4, when the XPRD is collected from about 5 to about 38 degrees twotheta (2 θ). Solid Form I may also be characterized by an X-ray powderdiffraction pattern, as measured using Cu K_(α) radiation, substantiallysimilar to FIG. 1 and an endothermic peak having an onset temperature atabout 318° C. as measured by differential scanning calorimetry in whichthe temperature is scanned at about 10° C. per minute. The presentapplication also provides a method for preparing crystal Form I of the6-fluoro benzimidazolyl urea compound by suspending a solid material ofthe free base in a solvent system comprising an alcohol and an ether andisolating the solid.

Another embodiment of the application provides solid Form II of thehydrochloride salt of the 6-fluoro benzimidazolyl urea compound,characterized by an X-ray powder diffraction pattern (XPRD) comprisingat least three approximate peak positions (degrees 2θ±0.2) when measuredusing Cu K_(α) radiation, selected from the group consisting of 6.7,9.2, 16.7, 18.6, 19.5, 20.5, 25.6, and 27.5, when the XPRD is collectedfrom about 5 to about 38 degrees 2 θ. Solid Form II may also becharacterized by an X-ray powder diffraction pattern, as measured usingCu K_(α) radiation, substantially similar to FIG. 4 and by anendothermic peak having an onset temperature at about 252° C. asmeasured by differential scanning calorimetry in which the temperatureis scanned at about 10° C. per minute. Solid Form II of thehydrochloride salt of the 6-fluoro benzimidazolyl urea compound may beprepared by suspending a free base of the 6-fluoro benzimidazolyl ureacompound in an acidic solvent mixture comprising one or more etherealsolvents and water.

A further embodiment of the present application is an amorphous Form IIIof the 6-fluoro benzimidazolyl urea compound (free base), characterizedby an X-ray powder diffraction pattern (XPRD) using Cu K_(α) radiation,characterized by a broad halo with no discernable diffraction peak. Afurther embodiment of the present application is a method for preparingan amorphous Form III of the 6-fluoro benzimidazolyl urea compound (freebase) comprising lyophilizing, spray drying, drum drying, or pulseconversion drying a solution of the 6-fluoro benzimidazolyl ureacompound.

Yet another embodiment of the present application is an amorphous FormIV of the mesylate salt of the 6-fluoro benzimidazolyl urea compoundcharacterized by an X-ray powder diffraction pattern (XPRD) using CuK_(α) radiation, characterized by a broad halo with no discernablediffraction peak.

DESCRIPTION OF FIGURES

FIG. 1 shows an X-ray powder diffraction pattern of solid Form I of the6-fluoro benzimidazolyl urea compound (free base) collected from about 5to about 38 degrees 2 θ.

FIG. 2 shows a DSC (DifferentialScanning calorimetry) thermogram ofsolid Form I of the 6-fluoro benzimidazolyl urea compound (free base).

FIG. 3 shows a TGA (thermal gravimetric analysis) thermogram of solidForm I of the 6-fluoro benzimidazolyl urea compound (free base).

FIG. 4 shows an X-ray powder diffraction pattern of solid Form II of thehydrochloride salt of the 6-fluoro benzimidazolyl urea compound.

FIG. 5 shows a DSC thermogram of solid Form II of the hydrochloride saltof the 6-fluoro benzimidazolyl urea compound.

FIG. 6 shows a TGA thermogram of solid Form II of the 6-fluorobenzimidazolyl urea compound.

FIG. 7 is an X-ray powder diffraction pattern of an amorphous Form IIIof the 6-fluoro benzimidazolyl urea compound (free base).

FIG. 8 shows a DSC thermogram of amorphous Form III of 6-fluorobenzimidazolyl urea (free base) exhibiting a small exotherm followed bythree larger endotherms.

FIG. 9 is an X-ray powder diffraction pattern of an amorphous Form IV ofthe mesylate salt of the 6-fluoro benzimidazolyl urea compound.

FIG. 10 is a ¹H-NMR spectrum of the mesylate salt of the 6-fluorobenzimidazolyl urea compound.

DETAILED DESCRIPTION

The present application is directed to novel, substantially pure solidforms of(R)-1-ethyl-3-[6-fluoro-5-[2-(1-hydroxy-1-methyl-ethyl)pyrimidin-5-yl]-7-(tetrahydrofuran-2-yl)-1H-benzimidazol-2-yl]urea(“the 6-fluoro benzimidazolyl urea compound”).

The inventors have discovered a free base crystalline form of thecompound (Form I), a crystalline form of a pharmaceutically acceptablesalt of the 6-fluoro benzimidazolyl urea compound (Form II,corresponding to a hydrochloride salt), an amorphous form of the freebase (Form III) as well as an amorphous form of the mesylate salt of thecompound (Form IV).

Thus, one aspect of the present application is a novel solid Form I ofthe 6-fluoro benzimidazolyl urea compound (free base). In one aspect,the present application provides a process for preparing solid Form I ofthe 6-fluoro benzimidazolyl urea compound.

A substantially pure solid Form I of the 6-fluoro benzimidazolyl ureacompound may be prepared from amorphous or crystalline compound bycontacting the compound with a solvent system comprising an alcohol andan ether and isolating the solid. The 6-fluoro benzimidazolyl ureacompound may be contacted with the solvent either by saturating asolution of the 6-fluoro benzimidazolyl urea compound in the solvent atambient temperature and allowing the mixture to stand for an extendedperiod of time (for example, overnight). Alternatively, the 6-fluorobenzimidazolyl urea compound may be dissolved in the solvent at elevatedtemperature, for example, at reflux, followed by cooling the solution toroom temperature or below and isolating solid Form I.

In one embodiment of the process, a substantially pure solid Form I ofthe 6-fluoro benzimidazolyl urea compound may be prepared from amorphousor crystalline form of the compound by preparing a saturated solution ofthe compound in a suitable solvent at room temperature and isolatingForm I which results. In practice this can be accomplished by dissolvinga sufficient amount of the 6-fluoro benzimidazolyl urea compound in thesolvent at elevated temperature (up to reflux) such that when thesolution is allowed to cool to room temperature a saturated solution isobtained, from which Form I precipitates and can be isolated. In otherembodiments, the 6-fluoro benzimidazolyl urea compound may be isolatedfrom a reaction mixture by modifying the solubility of the compound inthe solvent. For example, removing some or all of the solvent orlowering the mixture temperature may reduce the solubility of the6-fluoro benzimidazolyl urea compound and solid Form I may precipitate.Alternatively, adding a second solvent to the mixture may precipitatesolid Form I of the compound.

In one embodiment, the solvent for the preparation of Form I is amixture of ethanol and ethyl ether. Isolation of the resulting solidprovides Form I.

Solid Form I of the 6-fluoro benzimidazolyl urea compound may beidentified by the following characteristics: a broad endotherm at about250° C., a melt endotherm with an extrapolated onset of about 318° C. asdetermined by differential scanning calorimetry using 10° C. per minutescan rate; and an X-ray powder diffraction pattern essentially as shownin Table 1 and FIG. 1 wherein the XRPD patterns were measured using apowder diffractometer equipped with a Cu X-ray tube source. The samplewas illuminated with Cu Kα₁ radiation and XRPD data were collected fromabout 5 to about 40° 2θ. A person skilled in the art would recognizethat relative intensities of the XPRD peaks may significantly varydepending on the orientation of the sample under test and on the typeand setting of the instrument used, so that the intensities in the XPRDtraces included herein are to such extent illustrative and are notintended to be used for absolute comparisons.

FIG. 1 is an X-ray powder diffraction pattern of solid Form I of6-fluoro benzimidazolyl urea compound (free base) collected from about 5to about 40 degrees 2 θ. The peaks corresponding to the X-ray powderdiffraction pattern having a relative intensity greater than or equal to5% are listed in Table 1.

FIG. 2 shows a DSC thermogram of solid Form I of the 6-fluorobenzimidazolyl urea compound exhibiting a broad endotherm with an onsettransition at about 250° C. and an endotherm with an onset transition atabout 318° C. A person skilled in the art would recognize that the peakand onset temperatures of the endotherms may vary depending on theexperimental conditions. Data in FIG. 2 were collected equilibrating a2.5 mg sample of the solid at about 35° C. for about 10 minutes. Duringthe data collection period, the temperature was increased at a rate ofabout 10° C. per minute.

FIG. 3 is a TGA (thermal gravimetric analysis) thermogram of solid FormI of the 6-fluoro benzimidazolyl urea compound exhibiting an initialweight loss of about 15% percent in the 50 to 300° C. temperature rangewith additional weight loss of about 25% between 300 and 400° C.

In one embodiment, the present invention provides a solid Form I of thecompound of formula (I):

In another embodiment, the solid Form I is characterized by an X-raypowder diffraction pattern (XPRD) comprising at least three approximatepeak positions (degrees 2 θ±0.2) when measured using Cu K_(α) radiation,selected from the group consisting of 9.3, 11.7, 12.1, 12.4, 14.5, 15.9,16.3, 16.6, 18.5, 19.4, 21.5, 22.3, 22.8, 23.8, 24.5, 25.7, 28.1, 28.4,30.3, and 33.4, when the XPRD is collected from about 5 to about 38degrees 2 θ.

In another embodiment, the solid Form I is characterized by an X-raypowder diffraction pattern (XPRD) comprising at least three approximatepeak positions (degrees 2 θ±0.2) when measured using Cu K_(α) radiation,selected from the group consisting of 9.3, 16.6, 18.5, 19.4, 21.5, and25.7, when the XPRD is collected from about 5 to about 38 degrees 2 θ.

In another embodiment, the solid Form I is characterized by an X-raypowder diffraction pattern, as measured using Cu K_(c), radiation,substantially similar to FIG. 1.

In another embodiment, the solid Form I is further characterized by anendothermic peak having an onset temperature at about 318° C. asmeasured by differential scanning calorimetry in which the temperatureis scanned at about 10° C. per minute.

In another embodiment, the present invention provides a method forpreparing crystal Form I of the compound of formula (I) comprisingsuspending a solid material of the free base in solvent systemcomprising an alcohol and an ether and isolating the solid.

In another embodiment, the solid Form I is stable for at least one monthat 40° C. with relative humidity of up to 75%.

TABLE 1 XRPD pattern peaks for solid Form I of the 6-fluorobenzimidazolyl urea compound Position Relative Intensity Peak No. [°2θ][%] 1 9.29 66 2 11.74 14 3 12.13 14 4 12.37 15 5 13.71 5 6 14.18 6 714.54 19 8 15.90 23 9 16.32 24 10 16.59 100 11 18.49 92 12 19.43 87 1319.94 9 14 20.36 6 15 21.53 81 16 22.34 10 17 22.80 19 18 23.50 8 1923.75 13 20 24.45 28 21 25.09 6 22 25.67 58 23 26.39 5 24 26.69 6 2527.52 8 26 28.05 25 27 28.43 18 28 30.04 6 29 30.31 10 31 33.40 14 3234.07 6 33 35.22 5 34 37.27 5

In another aspect, the present application provides crystal Form II ofthe hydrochloric acid addition salt of the 6-fluoro benzimidazolyl ureacompound. In one embodiment, the present application provides a processfor preparing solid Form II of the 6-fluoro benzimidazolyl ureacompound. The pharmaceutically acceptable hydrochloric acid additionsalt of the 6-fluoro benzimidazolyl urea compound may be prepared by anymethod known to those skilled in the art.

In some embodiments, the hydrochloric acid addition salt of the 6-fluorobenzimidazolyl urea compound may precipitate out upon formation fromaddition of an acid to a solution of the compound. In other embodiments,the acid addition salt may be isolated from the reaction mixture bymodifying the solubility of the salt in the solvent. For example,removing some or all of the solvent or lowering the mixture temperaturemay reduce the solubility of the hydrochloride salt of the 6-fluorobenzimidazolyl urea compound and the salt precipitate. Alternatively,adding a second solvent to the mixture may precipitate the salt.

In further embodiments, gaseous hydrochloric acid may be bubbled througha solution of the 6-fluoro benzimidazolyl urea compound until a monoacid addition salt of the compound is prepared. In certain embodiments,stoichiometric amounts of hydrochloric acid and the 6-fluorobenzimidazolyl urea compound may be mixed together to form a mono acidaddition salt of the compound. For example, a solution of the 6-fluorobenzimidazolyl urea compound in a polar solvent may be mixed with astoichiometric amount of an aqueous solution of hydrochloric acid.Examples of polar solvents that may be suitable for preparing the solidForm II of hydrochloride salt of 6-fluoro benzimidazolyl urea compoundinclude ethers such as diethyl ether and tetrahydrofuran (THF).

In a particular embodiment, stoichiometric amounts of the 6-fluorobenzimidazolyl urea compound in THF and aqueous hydrochloric acid weremixed slowly and the mixture was stirred at room temperature overnight.A solid white hydrochloride salt of the 6-fluoro benzimidazolyl ureacompound precipitated out. The solid was isolated, washed with water anddried under vacuum.

Solid Form II of the 6-fluoro benzimidazolyl urea compound may beidentified by the following characteristics: a broad endotherm with apeak temperature of about 210° C., a melt endotherm with an extrapolatedonset of about 252° C. as determined by differential scanningcalorimetry using 10° C. per minute scan rate; and an X-ray powderdiffraction pattern essentially as shown in Table 2 and FIG. 4 whereinthe XRPD patterns were measured using a powder diffractometer equippedwith a Cu X-ray tube source. The sample was illuminated with Cu Kα₁radiation and XRPD data were collected from about 5 to about 40° 2θ. Aperson skilled in the art would recognize that relative intensities ofthe XPRD peaks may significantly vary depending on sample orientation.

FIG. 4 is an X-ray powder diffraction pattern of solid Form II of thehydrochloride salt of the 6-fluoro benzimidazolyl urea compoundcollected from about 5 to about 38 degrees 2 θ. The peaks correspondingto X-ray powder diffraction pattern having a relative intensity greaterthan or equal to 5% are listed in Table 2.

FIG. 5 shows a DSC thermogram of solid Form II of the hydrochloride saltof the 6-fluoro benzimidazolyl urea compound exhibiting an endotherm atabout 210° C. and an endotherm at about 252° C. A person skilled in theart would recognize that the peak and onset temperatures of theendotherms may vary depending on the experimental conditions. Data inFIG. 5 were collected equilibrating a 1 mg sample of the solid at about35° C. for about 10 minutes. During the data collection period, thetemperature was increased at a rate of about 10° C. per minute.

FIG. 6 is a TGA thermogram of solid Form II of the 6-fluorobenzimidazolyl urea compound exhibiting an initial weight loss of about8% percent between 100 and 220° C. followed by a second weight loss ofabout an additional 8% at between about 240 and 270° C. followed by athird weight loss of about 3% between 270 and 300° C. A person skilledin the art would recognize that the onset temperatures of the weightloss may vary depending on the experimental conditions. While applicantsdo not wish to be held to a particular explanation of the endotherm inthe DSC and weight loss in the TGA, it appears that the transition withlarge peak in the DSC is due to a melting transition coupled withdegradation of the material as suggested by the weight loss in the TGA.

In one embodiment, the present invention provides a hydrochloric acidsalt of the compound of formula (I):

In another embodiment, the hydrochloric acid salt is Form II solid form.

In another embodiment, the hydrochloric acid salt of Form II solid formis characterized by an X-ray powder diffraction pattern (XPRD)comprising at least three approximate peak positions (degrees 2 θ±0.2)when measured using Cu K_(c), radiation, selected from the groupconsisting of 6.7, 9.2, 16.7, 18.6, 19.5, 20.5, 25.6, and 27.5, when theXPRD is collected from about 5 to about 38 degrees 2 θ.

In another embodiment, the hydrochloric acid salt of Form II solid formis characterized by an X-ray powder diffraction pattern, as measuredusing Cu K_(α) radiation, substantially similar to FIG. 4.

In another embodiment, the hydrochloric acid salt of Form II solid formis further characterized by an endothermic peak having an onsettemperature at about 252° C. as measured by differential scanningcalorimetry in which the temperature is scanned at about 10° C. perminute.

In yet another embodiment, the present invention provides a method forpreparing solid Form II of the hydrochloride salt of the compound offormula (I) comprising suspending a free base of the 6-fluorobenzimidazolyl urea compound in an acidic solvent mixture comprising oneor more ethereal solvents and water.

In another embodiment, the hydrochloric acid salt of Form II solid formis stable for at least one month at 40° C. with relative humidity of upto 75%.

TABLE 2 XRPD pattern peaks for solid Form II of the 6-fluorobenzimidazolyl urea compound Peak Position Relative No. [°2θ] Intensity[%] 1 6.67 13 2 9.25 33 3 11.64 7 4 13.36 7 5 15.90 7 6 16.69 17 7 18.5912 8 18.81 7 9 19.51 14 10 20.48 100 11 22.59 7 12 24.57 5 13 25.61 1114 27.54 16

Another aspect of the present application is providing a compositioncomprising an amorphous 6-fluoro benzimidazolyl urea compound (freebase). The term “amorphous” as applied herein to 6-fluoro benzimidazolylurea compound or its salts refers to a solid state form wherein the6-fluoro benzimidazolyl urea molecules are generally present in adisordered arrangement and do not form a distinguishable crystal latticeor unit cell. When subjected to X-ray powder diffraction, a completelyamorphous compound does not produce a diffraction pattern characteristicof a crystalline form. The X-ray powder diffraction of a partiallyamorphous material may still lack features characteristic of a crystalform because the diffraction peaks from the crystalline portion of thesample may be too weak to be observable over the noise. FIG. 7 is anX-ray powder diffraction pattern of an amorphous form III of the6-fluoro benzimidazolyl urea compound (free base).

FIG. 8 shows a DSC thermogram of amorphous Form III of 6-fluorobenzimidazolyl urea (free base) exhibiting a small exotherm followed bythree larger endotherms. The small exotherm has an onset temperature of127° C. whereas the three endotherms have onset temperatures of 183° C.,226° C., and 279° C. A person skilled in the art would recognize thatthe peak and onset temperatures of the exotherm and the endotherms mayvary depending on the experimental conditions. Data in FIG. 8 werecollected equilibrating a 2.9 mg sample of the amorphous 6-fluorobenzimidazolyl urea compound at about 35° C. for about 10 minutes.During the data collection period, the temperature was increased at arate of about 10° C. per minute.

In another embodiment, the present invention provides an amorphous FormIII of the fluoro benzimidazolyl urea compound of formula I:

In another embodiment, the amorphous Form III of the fluorobenzimidazolyl urea compound is characterized by an X-ray powderdiffraction pattern (XPRD) using Cu K_(α) radiation, characterized by abroad halo with no discernable diffraction peak.

In yet another embodiment, the present invention provides a method forpreparing amorphous Form III of the 6-fluoro benzimidazolyl ureacompound comprising lyophilizing, spray drying, drum drying, or pulseconversion drying a solution of the 6-fluoro benzimidazolyl ureacompound.

In another aspect, the present application provides an amorphous solidphase Form IV of the mesylate salt of the 6-fluoro benzimidazolyl ureacompound. In one embodiment, the present application provides a processfor preparing solid Form IV of the mesylate salt of the 6-fluorobenzimidazolyl urea compound. A pharmaceutically acceptablemethanesulphonic acid salt of the 6-fluoro benzimidazolyl urea compoundmay be prepared by any method known to those skilled in the art. Forexample, a solution of methanesulphonic acid may be added to a solutionof the 6-fluoro benzimidazolyl urea compound until a mono acid additionsalt of the compound is prepared. In one embodiment, the mesylate saltof the 6-fluoro benzimidazolyl urea compound may precipitate out uponaddition of the acid to a solution of the 6-fluoro benzimidazolyl ureacompound. In other embodiments, the acid addition salt may be isolatedfrom the reaction mixture by modifying the solubility of the salt in thesolvent. For example, removing some or all of the solvent or loweringthe mixture temperature may reduce the solubility of the mesylate saltof the 6-fluoro benzimidazolyl urea compound and the salt precipitate.Thus, in some embodiments, the amorphous material is collected afterbeing precipitated from a solvent or from a solution after concentratingthe solution by evaporating some of the solvent, for example, using arotator evaporator. Alternatively, adding a second solvent to themixture may precipitate the salt.

The mesylate salt of the 6-fluoro benzimidazolyl urea compound may beconverted to an amorphous solid form using any method known to thoseskilled in the art. The amorphous 6-fluoro benzimidazolyl urea compoundmesylate salt may be characterized by the absence of a diffractionpattern characteristic of a crystalline form. The X-ray powderdiffraction of a partially amorphous 6-fluoro benzimidazolyl ureacompound mesylate salt may still lack features characteristic of acrystal form because the diffraction peaks from the crystalline portionof the sample may be too weak to be observable over the noise. FIG. 9 isan X-ray powder diffraction pattern of an amorphous Form IV of themesylate salt of the 6-fluoro benzimidazolyl urea compound.

In one embodiment, the amorphous mesylate salt of the 6-fluorobenzimidazolyl urea compound may be prepared by spray drying a solutionof the salt in appropriate solvent. Spray drying is well known in theart and is often used to dry thermally-sensitive materials such aspharmaceutical drugs. Spray drying also provides consistent particledistribution that can be reproduced fairly well. Any gas may be used todry the powder although air is commonly used. If the material issensitive to air, an inert gas, such nitrogen or argon, may be used. Anymethod that converts a solution, slurry, suspension or an emulsion ofthe salt to produce a solid powder may be suitable for preparing thesolid amorphous Form IV of the mesylate salt of the 6-fluorobenzimidazolyl urea compound. For example, freeze drying, drum drying,or pulse conversion drying may be used to produce an amorphous mesylatesalt of the 6-fluoro benzimidazolyl urea compound.

In one embodiment, a solution of the 6-fluoro benzimidazolyl ureacompound in a polar solvent may be spray dried using a nanospray dryerequipped a condenser. The inlet temperature may be kept between 80-120°C.

In another embodiment, the present invention provides an amorphous FormIV of the mesylate salt of the 6-fluoro benzimidazolyl urea compound offormula I:

In another embodiment, the amorphous Form IV of the mesylate salt of the6-fluorobenzimidazolyl urea compound is characterized by an X-ray powderdiffraction pattern (XPRD) using Cu K_(α) radiation, characterized by abroad halo with no discernable diffraction peak

It is to be understood that solid Forms I and II and amorphous solidForms III and IV of, respectively, free base and mesylate salt of the6-fluoro benzimidazolyl urea compound, in addition to having the XRPD,DSC, TGA and other characteristics described herein, may also possessother characteristics not described, such as but not limited to thepresence of water or one or more solvent molecules.

X-Ray Powder Diffraction (XRPD): The XRPD pattern of the crystallineforms were recorded at room temperature in reflection mode using aBruker D8 Discover system equipped with a sealed tube source and aHi-Star area detector (Bruker AXS, Madison, Wis.). The X-Ray generatorwas operating at a tension of 40 kV and a current of 35 mA. The powdersample was placed on a Si zero-background wafer. Two frames wereregistered with an exposure time of 120 s each. The data weresubsequently integrated over the range of 3°-41° 2 with a step size of0.02° and merged into one continuous pattern.

X-Ray Powder Diffraction (XRPD) for amorphous forms: The XRPD pattern ofthe amorphous solid form was recorded at room temperature in reflectionmode using Bruker D8 Advance system equipped with Vantec-1 positionsensitive detector (Bruker AXS, Madison, Wis.). The X-Ray generator wasoperating at a tension of 40 kV and a current of 45 mA. The powdersample was placed on a Si zero-background holder, spinning at 15 rpmduring the experiment in a continuous mode using variable slit at thedetector. Data was collected from 3 to 40 degrees with 0.0144653 degreeincrements (0.25 s/step).

Differential Scanning calorimetry (DSC): DSC was performed on a sampleof the material using a DSC Q2000 differential scanning calorimeter (TAInstruments, New Castle, Del.). The instrument was calibrated withindium. A sample of approximately 1-2 mg was weighed into an aluminumpan that was crimped using lids with either no pin-hole or pin-holelids. The DSC samples were scanned from 30° C. to temperatures indicatedin the plots at a heating rate of 10° C./min with 50 mL/min nitrogenflow. The samples run under modulated DSC (MDSC) were modulated + and−1° C. every 60 s with ramp rates of 2 or 3° C./min.

Data was collected by Thermal Advantage Q Series™ software and analyzedby Universal Analysis 2000 software (TA Instruments, New Castle, Del.).

Thermogravimetric analysis (TGA): A Model Q5000 ThermogravimetricAnalyzer (TA Instruments, New Castle, Del.) was used for TGAmeasurement. A sample with weight of approximately 3-5 mg was scannedfrom 30° C. to temperatures indicated on the plots at a heating rate of10° C./min. Data was collected by Thermal Advantage Q Series™ softwareand analyzed by Universal Analysis 2000 software (TA Instruments, NewCastle, Del.).

The present invention also provides a pharmaceutical compositioncomprising a compound of formula (I), or a pharmaceutically acceptablesalt thereof, and a pharmaceutically acceptable carrier, adjuvant, orvehicle.

The present invention also provides a method of controlling, treating orreducing the advancement, severity or effects of a nosocomial or anon-nosocomial bacterial infection in a patient, comprisingadministering to said patient a pharmaceutical composition comprising acompound of formula (I), or a pharmaceutically acceptable salt thereof.

In another embodiment, the present invention provides a method ofcontrolling, treating or reducing the advancement, severity or effectsof a nosocomial or a non-nosocomial bacterial infection in a patient,comprising administering to said patient a pharmaceutical compositioncomprising a compound of formula (I), or a pharmaceutically acceptablesalt thereof, wherein the bacterial infection is characterized by thepresence of one or more of Streptococcus pneumoniae, Staphylococcusepidermidis, Enterococcus faecalis, Staphylococcus aureus, Clostridiumdifficile, Moraxella catarrhalis, Neisseria gonorrhoeae, Neisseriameningitidis, Mycobacterium avium complex, Mycobacterium abscessus,Mycobacterium kansasii, Mycobacterium ulcerans, Chlamydophilapneumoniae, Chlamydia trachomatis, Haemophilus influenzae, Streptococcuspyogenes or β-haemolytic streptococci.

In another embodiment, the present invention provides a method ofcontrolling, treating or reducing the advancement, severity or effectsof a nosocomial or a non-nosocomial bacterial infection in a patient,comprising administering to said patient a pharmaceutical compositioncomprising a compound of formula (I), or a pharmaceutically acceptablesalt thereof, wherein the bacterial infection is selected from one ormore of the following: upper respiratory infections, lower respiratoryinfections, ear infections, pleuropulmonary and bronchial infections,complicated urinary tract infections, uncomplicated urinary tractinfections, intra-abdominal infections, cardiovascular infections, ablood stream infection, sepsis, bacteremia, CNS infections, skin andsoft tissue infections, GI infections, bone and joint infections,genital infections, eye infections, or granulomatous infections,uncomplicated skin and skin structure infections (uSSSI), complicatedskin and skin structure infections (cSSSI), catheter infections,pharyngitis, sinusitis, otitis externa, otitis media, bronchitis,empyema, pneumonia, community-acquired bacterial pneumoniae (CABP),hospital-acquired pneumonia (HAP), hospital-acquired bacterialpneumonia, ventilator-associated pneumonia (VAP), diabetic footinfections, vancomycin resistant enterococci infections, cystitis andpyelonephritis, renal calculi, prostatitis, peritonitis, complicatedintra-abdominal infections (cIAI) and other inter-abdominal infections,dialysis-associated peritonitis, visceral abscesses, endocarditis,myocarditis, pericarditis, transfusion-associated sepsis, meningitis,encephalitis, brain abscess, osteomyelitis, arthritis, genital ulcers,urethritis, vaginitis, cervicitis, gingivitis, conjunctivitis,keratitis, endophthalmitisa, an infection in cystic fibrosis patients oran infection of febrile neutropenic patients.

In another embodiment, the bacterial infection is selected from one ormore of the following: community-acquired bacterial pneumoniae (CABP),hospital-acquired pneumonia (HAP), hospital-acquired bacterialpneumonia, ventilator-associated pneumonia (VAP), bacteremia, diabeticfoot infections, catheter infections, uncomplicated skin and skinstructure infections (uSSSI), complicated skin and skin structureinfections (cSSSI), vancomycin resistant enterococci infections orosteomyelitis.

According to another embodiment, the invention provides a method ofdecreasing or inhibiting bacterial quantity in a biological sample. Thismethod comprises contacting said biological sample with a compound offormula (I) or a pharmaceutically acceptable salt thereof.

The term “biological sample”, as used herein, includes cell cultures orextracts thereof; biopsied material obtained from a mammal or extractsthereof; and blood, saliva, urine, feces, semen, tears, or other bodyfluids or extracts thereof. The term “biological sample” also includesliving organisms, in which case “contacting a compound of this inventionwith a biological sample” is synonymous with the term “administeringsaid compound or composition comprising said compound) to a mammal”.

The gyrase and/or topoisomerase IV inhibitors of this invention, orpharmaceutical salts thereof, may be formulated into pharmaceuticalcompositions for administration to animals or humans. Thesepharmaceutical compositions effective to treat or prevent a bacterialinfection which comprise the gyrase and/or topoisomerase IV inhibitor inan amount sufficient to measurably decrease bacterial quantity and apharmaceutically acceptable carrier, are another embodiment of thepresent invention. The term “measurably decrease bacterial quantity”, asused herein means a measurable change in the number of bacteria betweena sample containing said inhibitor and a sample containing onlybacteria.

According to another embodiment, the methods of the present inventionare useful to treat patients in the veterinarian field including, butnot limited to, zoo, laboratory, human companion, and farm animalsincluding primates, rodents, reptiles and birds. Examples of saidanimals include, but are not limited to, guinea pigs, hamsters, gerbils,rat, mice, rabbits, dogs, cats, horses, pigs, sheep, cows, goats, deer,rhesus monkeys, monkeys, tamarinds, apes, baboons, gorillas,chimpanzees, orangutans, gibbons, ostriches, chickens, turkeys, ducks,and geese.

The term “non-nosocomial infections” is also referred to as communityacquired infections.

In another embodiment, the bacterial infection is characterized by thepresence of one or more of Streptococcus pneumoniae, Enterococcusfaecalis, or Staphylococcus aureus.

In another embodiment, the bacterial infection is characterized by thepresence of one or more of E. coli, Moraxella catarrhalis, orHaemophilus influenzae.

In another embodiment, the bacterial infection is characterized by thepresence of one or more of Clostridium difficile, Neisseria gonorrhoeae,Neisseria meningitidis, Mycobacterium avium complex, Mycobacteriumabscessus, Mycobacterium kansasii, Mycobacterium ulcerans, Chlamydophilapneumoniae and Chlamydia tracomatis.

In another embodiment, the bacterial infection is characterized by thepresence of one or more of Streptococcus pneumoniae, Staphylococcusepidermidis, Enterococcus faecalis, Staphylococcus aureus, Clostridiumdifficile, Moraxella catarrhalis, Neisseria gonorrhoeae, Neisseriameningitidis, Mycobacterium avium complex, Mycobacterium abscessus,Mycobacterium kansasii, Mycobacterium ulcerans, Chlamydophilapneumoniae, Chlamydia trachomatis, Haemophilus influenzae, Streptococcuspyogenes or β-haemolytic streptococci.

In some embodiments, the bacterial infection is characterized by thepresence of one or more of Methicillin resistant Staphylococcus aureus,Fluoroquinolone resistant Staphylococcus aureus, Vancomycin intermediateresistant Staphylococcus aureus, Linezolid resistant Staphylococcusaureus, Penicillin resistant Streptococcus pneumoniae, Macrolideresistant Streptococcus pneumoniae, Fluoroquinolone resistantStreptococcus pneumoniae, Vancomycin resistant Enterococcus faecalis,Linezolid resistant Enterococcus faecalis, Fluoroquinolone resistantEnterococcus faecalis, Vancomycin resistant Enterococcus faecium,Linezolid resistant Enterococcus faecium, Fluoroquinolone resistantEnterococcus faecium, Ampicillin resistant Enterococcus faecium,Macrolide resistant Haemophilus influenzae, β-lactam resistantHaemophilus influenzae, Fluoroquinolone resistant Haemophilusinfluenzae, β-lactam resistant Moraxella catarrhalis, Methicillinresistant Staphylococcus epidermidis, Methicillin resistantStaphylococcus epidermidis, Vancomycin resistant Staphylococcusepidermidis, Fluoroquinolone resistant Staphylococcus epidermidis,Macrolide resistant Mycoplasma pneumoniae, Isoniazid resistantMycobacterium tuberculosis, Rifampin resistant Mycobacteriumtuberculosis, Methicillin resistant Coagulase negative staphylococcus,Fluoroquinolone resistant Coagulase negative staphylococcus,Glycopeptide intermediate resistant Staphylococcus aureus, Vancomycinresistant Staphylococcus aureus, Hetero vancomycin intermediateresistant Staphylococcus aureus, Hetero vancomycin resistantStaphylococcus aureus, Macrolide-Lincosamide-Streptogramin resistantStaphylococcus, β-lactam resistant Enterococcus faecalis, β-lactamresistant Enterococcus faecium, Ketolide resistant Streptococcuspneumoniae, Ketolide resistant Streptococcus pyogenes, Macrolideresistant Streptococcus pyogenes, Vancomycin resistant staphylococcusepidermidis, Fluoroquinolone resistant Neisseria gonorrhoeae, MultidrugResistant Pseudomonas aeruginosa or Cephalosporin resistant Neisseriagonorrhoeae.

According to another embodiment, the Methicillin resistant Staphylococciare selected from Methicillin resistant Staphylococcus aureus,Methicillin resistant Staphylococcus epidermidis, or Methicillinresistant Coagulase negative staphylococcus.

In some embodiments, a form of a compound of formula (I), or apharmaceutically acceptable salt thereof, is used to treat communityacquired MRSA (i.e., cMRSA).

In other embodiments, a form of a compound of formula (I), or apharmaceutically acceptable salt thereof, is used to treat daptomycinresistant organism including, but not limited to, Daptomycin resistantEnterococcus faecium and Daptomycin resistant Staphylococcus aureus.

According to another embodiment, the Fluoroquinolone resistantStaphylococci are selected from Fluoroquinolone resistant Staphylococcusaureus, Fluoroquinolone resistant Staphylococcus epidermidis, orFluoroquinolone resistant Coagulase negative staphylococcus.

According to another embodiment, the Glycopeptide resistantStaphylococci are selected from Glycopeptide intermediate resistantStaphylococcus aureus, Vancomycin resistant Staphylococcus aureus,Vancomycin intermediate resistant Staphylococcus aureus, Heterovancomycin intermediate resistant Staphylococcus aureus, or Heterovancomycin resistant Staphylococcus aureus.

According to another embodiment, the Macrolide-Lincosamide-Streptograminresistant Staphylococci is Macrolide-Lincosamide-Streptogramin resistantStaphylococcus aureus.

According to another embodiment, the Linezolid resistant Enterococci areselected from Linezolid resistant Enterococcus faecalis, or Linezolidresistant Enterococcus faecium.

According to another embodiment, the Glycopeptide resistant Enterococciare selected from Vancomycin resistant Enterococcus faecium orVancomycin resistant Enterococcus faecalis.

According to another embodiment, the β-lactam resistant Enterococcusfaecalis is β-lactam resistant Enterococcus faecium.

According to another embodiment, the Penicillin resistant Streptococciis Penicillin resistant Streptococcus pneumoniae.

According to another embodiment, the Macrolide resistant Streptococci isMacrolide resistant Streptococcus pneumonia.

According to another embodiment, the Ketolide resistant Streptococci areselected from Macrolide resistant Streptococcus pneumoniae and Ketolideresistant Streptococcus pyogenes.

According to another embodiment, the Fluoroquinolone resistantStreptococci is Fluoroquinolone resistant Streptococcus pneumoniae.

According to another embodiment, the β-lactam resistant Haemophilus isβ-lactam resistant Haemophilus influenzae.

According to another embodiment, the Fluoroquinolone resistantHaemophilus is Fluoroquinolone resistant Haemophilus influenzae.

According to another embodiment, the Macrolide resistant Haemophilus isMacrolide resistant Haemophilus influenzae.

According to another embodiment, the Macrolide resistant Mycoplasma isMacrolide resistant Mycoplasma pneumoniae.

According to another embodiment, the Isoniazid resistant Mycobacteriumis Isoniazid resistant Mycobacterium tuberculosis.

According to another embodiment, the Rifampin resistant Mycobacterium isRifampin resistant Mycobacterium tuberculosis.

According to another embodiment, the β-lactam resistant Moraxella isβ-lactam resistant Moraxella catarrhalis.

According to another embodiment, the bacterial infection ischaracterized by the presence of one or more of the following:Methicillin resistant Staphylococcus aureus, Fluoroquinolone resistantStaphylococcus aureus, Vancomycin intermediate resistant Staphylococcusaureus, Linezolid resistant Staphylococcus aureus, Penicillin resistantStreptococcus pneumoniae, Macrolide resistant Streptococcus pneumoniae,Fluoroquinolone resistant Streptococcus pneumoniae, Vancomycin resistantEnterococcus faecalis, Linezolid resistant Enterococcus faecalis,Fluoroquinolone resistant Enterococcus faecalis, Vancomycin resistantEnterococcus faecium, Linezolid resistant Enterococcus faecium,Fluoroquinolone resistant Enterococcus faecium, Ampicillin resistantEnterococcus faecium, Macrolide resistant Haemophilus influenzae,β-lactam resistant Haemophilus influenzae, Fluoroquinolone resistantHaemophilus influenzae, β-lactam resistant Moraxella catarrhalis,Methicillin resistant Staphylococcus epidermidis, Methicillin resistantStaphylococcus epidermidis, Vancomycin resistant Staphylococcusepidermidis, Fluoroquinolone resistant Staphylococcus epidermidis,Macrolide resistant Mycoplasma pneumoniae, Isoniazid resistantMycobacterium tuberculosis, Rifampin resistant Mycobacteriumtuberculosis, Fluoroquinolone resistant Neisseria gonorrhoeae orCephalosporin resistant Neisseria gonorrhoeae.

According to another embodiment, the bacterial infection ischaracterized by the presence of one or more of the following:Methicillin resistant Staphylococcus aureus, Methicillin resistantStaphylococcus epidermidis, Methicillin resistant Coagulase negativestaphylococcus, Fluoroquinolone resistant Staphylococcus aureus,Fluoroquinolone resistant Staphylococcus epidermidis, Fluoroquinoloneresistant Coagulase negative staphylococcus, Vancomycin resistantStaphylococcus aureus, Glycopeptide intermediate resistantStaphylococcus aureus, Vancomycin resistant Staphylococcus aureus,Vancomycin intermediate resistant Staphylococcus aureus, Heterovancomycin intermediate resistant Staphylococcus aureus, Heterovancomycin resistant Staphylococcus aureus, Vancomycin resistantEnterococcus faecium, Vancomycin resistant Enterococcus faecalis,Penicillin resistant Streptococcus pneumoniae, Macrolide resistantStreptococcus pneumoniae, Fluoroquinolone resistant Streptococcuspneumoniae, Macrolide resistant Streptococcus pyogenes, or β-lactamresistant Haemophilus influenzae.

According to another embodiment, the bacterial infection ischaracterized by the presence of one or more of the following:Methicillin resistant Staphylococcus aureus, Vancomycin resistantEnterococcus faecium, Vancomycin resistant Enterococcus faecalis,Vancomycin resistant Staphylococcus aureus, Vancomycin intermediateresistant Staphylococcus aureus, Hetero vancomycin intermediateresistant Staphylococcus aureus, Hetero vancomycin resistantStaphylococcus aureus, Multidrug Resistant Pseudomonas aeruginosa,Isoniazid resistant Mycobacterium tuberculosis, and Rifampin resistantMycobacterium tuberculosis.

Pharmaceutically acceptable salts of the compounds of this inventioninclude those derived from pharmaceutically acceptable inorganic andorganic acids and bases. Examples of suitable acid salts includeacetate, adipate, alginate, aspartate, benzoate, benzenesulfonate,bisulfate, butyrate, citrate, camphorate, camphorsulfonate,cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate,formate, fumarate, glucoheptanoate, glycerophosphate, glycolate,hemisulfate, heptanoate, hexanoate, hydrochloride, hydrobromide,hydroiodide, 2-hydroxyethanesulfonate, lactate, maleate, malonate,methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, palmoate,pectinate, persulfate, 3-phenylpropionate, phosphate, picrate, pivalate,propionate, salicylate, succinate, sulfate, tartrate, thiocyanate,tosylate and undecanoate. Other acids, such as oxalic, while not inthemselves pharmaceutically acceptable, may be employed in thepreparation of salts useful as intermediates in obtaining the compoundsof the invention and their pharmaceutically acceptable acid additionsalts.

Salts derived from appropriate bases include alkali metal (e.g., sodiumand potassium), alkaline earth metal (e.g., magnesium), ammonium andN⁺(C₁₋₄ alkyl)₄ salts. This invention also envisions the quaternizationof any basic nitrogen-containing groups of the compounds disclosedherein. Water or oil-soluble or dispersible products may be obtained bysuch quaternization.

Pharmaceutical compositions of this invention comprise a compound offormula (I) or a pharmaceutically acceptable salt thereof and apharmaceutically acceptable carrier. Such compositions may optionallycomprise an additional therapeutic agent. Such agents include, but arenot limited to, an antibiotic, an anti-inflammatory agent, a matrixmetalloprotease inhibitor, a lipoxygenase inhibitor, a cytokineantagonist, an immunosuppressant, an anti-cancer agent, an anti-viralagent, a cytokine, a growth factor, an immunomodulator, a prostaglandinor an anti-vascular hyperproliferation compound.

The term “pharmaceutically acceptable carrier” refers to a non-toxiccarrier that may be administered to a patient, together with a compoundof this invention, and which does not destroy the pharmacologicalactivity thereof.

Pharmaceutically acceptable carriers that may be used in thepharmaceutical compositions of this invention include, but are notlimited to, ion exchangers, alumina, aluminum stearate, lecithin, serumproteins, such as human serum albumin, buffer substances such asphosphates, glycine, sorbic acid, potassium sorbate, partial glyceridemixtures of saturated vegetable fatty acids, water, salts orelectrolytes, such as protamine sulfate, disodium hydrogen phosphate,potassium hydrogen phosphate, sodium chloride, zinc salts, colloidalsilica, magnesium trisilicate, polyvinyl pyrrolidone, cellulose-basedsubstances, polyethylene glycol, sodium carboxymethylcellulose,polyacrylates, waxes, polyethylene-polyoxypropylene-block polymers, woolfat and self-emulsifying drug delivery systems (SEDDS) such asalpha-tocopherol, polyethyleneglycol 1000 succinate, or other similarpolymeric delivery matrices.

The term “pharmaceutically effective amount” refers to an amounteffective in treating or ameliorating a bacterial infection in apatient. The term “prophylactically effective amount” refers to anamount effective in preventing or substantially lessening a bacterialinfection in a patient.

Depending upon the particular condition, or disease state, to be treatedor prevented, additional therapeutic agents, which are normallyadministered to treat or prevent that condition, may be administeredtogether with the inhibitors of this invention. Such therapeutic agentsinclude, but are not limited to, an antibiotic, an anti-inflammatoryagent, a matrix metalloprotease inhibitor, a lipoxygenase inhibitor, acytokine antagonist, an immunosuppressant, an anti-cancer agent, ananti-viral agent, a cytokine, a growth factor, an immunomodulator, aprostaglandin or an anti-vascular hyperproliferation compound.

The compounds of this invention may be employed in a conventional mannerfor controlling bacterial infections levels in vivo and for treatingdiseases or reducing the advancement or severity of effects which aremediated by bacteria. Such methods of treatment, their dosage levels andrequirements may be selected by those of ordinary skill in the art fromavailable methods and techniques.

For example, a compound of this invention may be combined with apharmaceutically acceptable adjuvant for administration to a patientsuffering from a bacterial infection or disease in a pharmaceuticallyacceptable manner and in an amount effective to lessen the severity ofthat infection or disease.

Alternatively, the compounds of this invention may be used incompositions and methods for treating or protecting individuals againstbacterial infections or diseases over extended periods of time. In oneembodiment, the compounds of this invention may be used in compositionsand methods for treating or protecting individuals against bacterialinfections or diseases over a 1-2 week period. In another embodiment,the compounds of this invention may be used in compositions and methodsfor treating or protecting individuals against bacterial infections ordiseases over a 4-8 week period (for example, in the treatment ofpatients with or at risk for developing endocarditis or osteomyelitis).In another embodiment, the compounds of this invention may be used incompositions and methods for treating or protecting individuals againstbacterial infections or diseases over an 8-12 week period. The compoundsmay be employed in such compositions either alone or together with othercompounds of this invention in a manner consistent with the conventionalutilization of enzyme inhibitors in pharmaceutical compositions. Forexample, a compound of this invention may be combined withpharmaceutically acceptable adjuvants conventionally employed invaccines and administered in prophylactically effective amounts toprotect individuals over an extended period of time against bacterialinfections or diseases.

In some embodiments, compounds of formula (I), or a pharmaceuticallyacceptable salt thereof, may be used prophylactically to prevent abacterial infection. In some embodiments, compounds of formula (I), or apharmaceutically acceptable salt thereof, may be used before, during orafter a dental or surgical procedure to prevent opportunistic infectionssuch as those encountered in bacterial endocarditis. In otherembodiments, compounds of formula (I), or a pharmaceutically acceptablesalt thereof, may be used prophylactically in dental procedures,including but not limited to extractions, periodontal procedures, dentalimplant placements and endodontic surgery. In other embodiments,compounds of formula (I), or a pharmaceutically acceptable salt thereof,may be used prophylactically in surgical procedures including but notlimited to general surgery, respiratory surgery(tonsillectomy/adenoidectomy), gastrointestinal surgery (upper GI andelective small bowel surgery, esophageal sclerotherapy and dilation,large bowel resections, acute appendectomy), trauma surgery (penetratingabdominal surgery), genito-urinary tract surgery (prostatectomy,urethral dilation, cystoscopy, vaginal or abdominal hysterectomy,cesarean section), transplant surgery (kidney, liver, pancreas or kidneytransplantation), head and neck surgery (skin excisions, neckdissections, laryngectomy, head and neck cancer surgeries, mandibularfractures), orthopaedic surgery (total joint replacement, traumatic openfractures), vascular surgery (peripheral vascular procedures),cardiothoracic surgery, coronary bypass surgery, pulmonary resection andneurosurgery.

The term “prevent a bacterial infection” as used herein, unlessotherwise indicated, means the prophylactic use of an antibiotic, suchas a gyrase and/or topoisomerase IV inhibitor of the present invention,to prevent a bacterial infection. Treatment with a gyrase and/ortopoisomerase IV inhibitor could be done prophylactically to prevent aninfection caused by an organism that is susceptible to the gyrase and/ortopoisomerase IV inhibitor. One general set of conditions whereprophylactic treatment could be considered is when an individual is morevulnerable to infection due to, for example, weakened immunity, surgery,trauma, presence of an artificial device in the body (temporary orpermanent), an anatomical defect, exposure to high levels of bacteria orpossible exposure to a disease-causing pathogen. Examples of factorsthat could lead to weakened immunity include chemotherapy, radiationtherapy, diabetes, advanced age, HIV infection, and transplantation. Anexample of an anatomical defect would be a defect in the heart valvethat increases the risk of bacterial endocarditis. Examples ofartificial devices include artificial joints, surgical pins, catheters,etc. Another set of situations where prophylactic use of a gyrase and/ortopoisomerase IV inhibitor might be appropriate would be to prevent thespread of a pathogen between individuals (direct or indirect). Aspecific example of prophylactic use to prevent the spread of a pathogenis the use of a gyrase and/or topoisomerase IV inhibitor by individualsin a healthcare institution (for example a hospital or nursing home).

The compounds of formula (I), or a pharmaceutically acceptable saltthereof, may also be co-administered with other antibiotics to increasethe effect of therapy or prophylaxis against various bacterialinfections. When the compounds of this invention are administered incombination therapies with other agents, they may be administeredsequentially or concurrently to the patient. Alternatively,pharmaceutical or prophylactic compositions according to this inventioncomprise a combination of a compound of formula (I), or apharmaceutically acceptable salt thereof, and another therapeutic orprophylactic agent.

In some embodiments, the additional therapeutic agent or agents is anantibiotic selected from a natural penicillin, a penicillinase-resistantpenicillin, an antipseudomonal penicillin, an aminopenicillin, a firstgeneration cephalosporin, a second generation cephalosporin, a thirdgeneration cephalosporin, a fourth generation cephalosporin, acarbapenem, a cephamycin, a quinolone, a fluoroquinolone, anaminoglycoside, a macrolide, a ketolide, a polymyxin, a tetracycline, aglycopeptide, a streptogramin, an oxazolidinone, a rifamycin, or asulfonamide.

In some embodiments, the additional therapeutic agent or agents is anantibiotic selected from a penicillin, a cephalosporin, a quinolone, anaminoglycoside or an oxazolidinone.

In other embodiments, the additional therapeutic agents are selectedfrom a natural penicillin including Benzathine penicillin G, PenicillinG and Penicillin V, from a penicillinase-resistant penicillin includingCloxacillin, Dicloxacillin, Nafcillin and Oxacillin, from aantipseudomonal penicillin including Carbenicillin, Mezlocillin,Pipercillin, Pipercillin/tazobactam, Ticaricillin andTicaricillin/Clavulanate, from an aminopenicillin including Amoxicillin,Ampicillin and Ampicillin/Sulbactam, from a first generationcephalosporin including Cefazolin, Cefadroxil, Cephalexin andCephadrine, from a second generation cephalosporin including Cefaclor,Cefaclor-CD, Cefamandole, Cefonacid, Cefprozil, Loracarbef andCefuroxime, from a third generation cephalosporin including Cefdinir,Cefixime, Cefoperazone, Cefotaxime, Cefpodoxime, Ceftazidime,Ceftibuten, Ceftizoxme and Ceftriaxone, from a fourth generationcephalosporin including Cefepime, Ceftaroline and Ceftobiprole, from aCephamycin including Cefotetan and Cefoxitin, from a carbapenemincluding Doripenem, Imipenem and Meropenem, from a monobactam includingAztreonam, from a quinolone including Cinoxacin, Nalidixic acid,Oxolininc acid and Pipemidic acid, from a fluoroquinolone includingBesifloxacin, Ciprofloxacin, Enoxacin, Gatifloxacin, Grepafloxacin,Levofloxacin, Lomefloxacin, Moxifloxacin, Norfloxacin, Ofloxacin andSparfloxacin, from an aminoglycoside including Amikacin, Gentamicin,Kanamycin, Neomycin, Netilmicin, Spectinomycin, Streptomycin andTobramycin, from a macrolide including Azithromycin, Clarithromycin andErythromycin, from a ketolide including Telithromycin, from aTetracycline including Chlortetracycline, Demeclocycline, Doxycycline,Minocycline and Tetracycline, from a glycopeptide including Oritavancin,Dalbavancin, Telavancin, Teicoplanin and Vancomycin, from astreptogramin including Dalfopristin/quinupristin, from an oxazolidoneincluding Linezolid, from a Rifamycin including Rifabutin and Rifampinand from other antibiotics including bactitracin, colistin, Tygacil,Daptomycin, chloramphenicol, clindamycin, isoniazid, metronidazole,mupirocin, polymyxin B, pyrazinamide, trimethoprim/sulfamethoxazole andsulfisoxazole.

In other embodiments, the additional therapeutic agents are selectedfrom a natural penicillin including Penicillin G, from apenicillinase-resistant penicillin including Nafcillin and Oxacillin,from an antipseudomonal penicillin including Pipercillin/tazobactam,from an aminopenicillin including Amoxicillin, from a first generationcephalosporin including Cephalexin, from a second generationcephalosporin including Cefaclor, Cefaclor-CD and Cefuroxime, from athird generation cephalosporin including Ceftazidime and Ceftriaxone,from a fourth generation cephalosporin including Cefepime, from acarbapenem including Imepenem, Meropenem, Ertapenem, Doripenem,Panipenem and Biapenem, a fluoroquinolone including Ciprofloxacin,Gatifloxacin, Levofloxacin and Moxifloxacin, from an aminoglycosideincluding Tobramycin, from a macrolide including Azithromycin andClarithromycin, from a Tetracycline including Doxycycline, from aglycopeptide including Vancomycin, from a Rifamycin including Rifampinand from other antibiotics including isoniazid, pyrazinamide, Tygacil,Daptomycin or trimethoprim/sulfamethoxazole.

In some embodiments, a solid form of a compound of formula (I), or apharmaceutically acceptable salt thereof, can be administered for thetreatment of a gram positive infection. In some embodiments, thecomposition is a solid, liquid (e.g., a suspension), or an iv (e.g., aform of the formula (I) compound, or a pharmaceutically acceptable saltthereof, is dissolved into a liquid and administered iv) composition. Insome embodiments, the composition including a formula (I) compound, or apharmaceutically acceptable salt thereof, is administered in combinationwith an additional antibiotic agent, for example, a natural penicillin,a penicillinase-resistant penicillin, an antipseudomonal penicillin, anaminopenicillin, a first generation cephalosporin, a second generationcephalosporin, a third generation cephalosporin, a fourth generationcephalosporin, a carbapenem, a cephamycin, a quinolone, afluoroquinolone, an aminoglycoside, a macrolide, a ketolide, apolymyxin, a tetracycline, a glycopeptide, a streptogramin, anoxazolidinone, a rifamycin, or a sulfonamide. In some embodiments, thecomposition including a solid form of a formula (I) compound, or apharmaceutically acceptable salt thereof, is administered orally, andthe additional antibiotic agent, for example, a natural penicillin, apenicillinase-resistant penicillin, an antipseudomonal penicillin, anaminopenicillin, a first generation cephalosporin, a second generationcephalosporin, a third generation cephalosporin, a fourth generationcephalosporin, a carbapenem, a cephamycin, a quinolone, afluoroquinolone, an aminoglycoside, a macrolide, a ketolide, apolymyxin, a tetracycline, a glycopeptide, a streptogramin, anoxazolidinone, a rifamycin, or a sulfonamide is administered iv.

In some embodiments, a solid form of a formula (I) compound, or apharmaceutically acceptable salt thereof, can be administered for thetreatment of a gram negative infection. In some embodiments, thecomposition is a solid, liquid (e.g., a suspension), or an iv (e.g., aform of a formula (I) compound, or a pharmaceutically acceptable saltthereof, is dissolved into a liquid and administered iv) composition. Insome embodiments the composition including a formula (I) compound, or apharmaceutically acceptable salt thereof, is administered in combinationwith an additional antibiotic agent, selected from a: naturalpenicillin, a penicillinase-resistant penicillin, an antipseudomonalpenicillin, an aminopenicillin, a first generation cephalosporin, asecond generation cephalosporin, a third generation cephalosporin, afourth generation cephalosporin, a carbapenem, a cephamycin, amonobactam, a quinolone, a fluoroquinolone, an aminoglycoside, amacrolide, a ketolide, a polymyxin, tetracycline or a sulfonamide. Insome embodiments, the composition including a solid form of a formula(I) compound, or a pharmaceutically acceptable salt thereof, isadministered orally, and the additional antibiotic agent, for example, anatural penicillin, a penicillinase-resistant penicillin, anantipseudomonal penicillin, an aminopenicillin, a first generationcephalosporin, a second generation cephalosporin, a third generationcephalosporin, a fourth generation cephalosporin, a carbapenem, acephamycin, a monobactam, a quinolone, a fluoroquinolone, anaminoglycoside, a macrolide, a ketolide, a polymyxin, tetracycline or asulfonamide is administered orally. In some embodiments, the additionaltherapeutic agent is administered iv.

The additional therapeutic agents described above may be administeredseparately, as part of a multiple dosage regimen, from theinhibitor-containing composition. Alternatively, these agents may bepart of a single dosage form, mixed together with the inhibitor in asingle composition.

The pharmaceutical compositions of this invention may be administeredorally, parenterally, by inhalation spray, topically, rectally, nasally,buccally, vaginally or via an implanted reservoir. The pharmaceuticalcompositions of this invention may contain any conventional non-toxicpharmaceutically-acceptable carriers, adjuvants or vehicles. In somecases, the pH of the formulation may be adjusted with pharmaceuticallyacceptable acids, bases or buffers to enhance the stability of theformulated compound or its delivery form. The term parenteral as usedherein includes subcutaneous, intracutaneous, intravenous,intramuscular, intra-articular, intrasynovial, intrasternal,intrathecal, intralesional and intracranial injection or infusiontechniques.

The pharmaceutical, compositions may be in the form of a sterileinjectable preparation, for example, as a sterile injectable aqueous oroleaginous suspension. This suspension may be formulated according totechniques known in the art using suitable dispersing or wetting agents(such as, for example, Tween 80) and suspending agents. The sterileinjectable preparation may also be a sterile injectable solution orsuspension in a non-toxic parenterally-acceptable diluent or solvent,for example, as a solution in 1,3-butanediol. Among the acceptablevehicles and solvents that may be employed are mannitol, water, Ringer'ssolution and isotonic sodium chloride solution. In addition, sterile,fixed oils are conventionally employed as a solvent or suspendingmedium. For this purpose, any bland fixed oil may be employed includingsynthetic mono- or diglycerides. Fatty acids, such as oleic acid and itsglyceride derivatives are useful in the preparation of injectables, asare natural pharmaceutically-acceptable oils, such as olive oil orcastor oil, especially in their polyoxyethylated versions. These oilsolutions or suspensions may also contain a long-chain alcohol diluentor dispersant, such as those described in Pharmacopeia Helvetica, or asimilar alcohol.

The pharmaceutical compositions of this invention may be orallyadministered in any orally acceptable dosage form including, but notlimited to, capsules, tablets, and aqueous suspensions and solutions. Inthe case of tablets for oral use, carriers which are commonly usedinclude lactose and corn starch. Lubricating agents, such as magnesiumstearate, are also typically added. For oral administration in a capsuleform, useful diluents include lactose and dried corn starch. Whenaqueous suspensions and solutions and propylene glycol are administeredorally, the active ingredient is combined with emulsifying andsuspending agents. If desired, certain sweetening and/or flavoringand/or coloring agents may be added.

The pharmaceutical compositions of this invention may also beadministered in the form of suppositories for rectal administration.These compositions can be prepared by mixing a compound of thisinvention with a suitable non-irritating excipient which is solid atroom temperature but liquid at the rectal temperature and therefore willmelt in the rectum to release the active components. Such materialsinclude, but are not limited to, cocoa butter, beeswax and polyethyleneglycols.

Topical administration of the pharmaceutical compositions of thisinvention is especially useful when the desired treatment involves areasor organs readily accessible by topical application. For applicationtopically to the skin, the pharmaceutical composition should beformulated with a suitable ointment containing the active componentssuspended or dissolved in a carrier. Carriers for topical administrationof the compounds of this invention include, but are not limited to,mineral oil, liquid petroleum, white petroleum, propylene glycol,polyoxyethylene, polyoxypropylene, emulsifying wax and water.Alternatively, the pharmaceutical composition can be formulated with asuitable lotion or cream containing the active compound suspended ordissolved in a carrier. Suitable carriers include, but are not limitedto, mineral oil, sorbitan monostearate, polysorbate 60, cetyl esterswax, cetearyl alcohol, 2-octyldodecanol, benzyl alcohol and water. Thepharmaceutical compositions of this invention may also be topicallyapplied to the lower intestinal tract by rectal suppository formulationor in a suitable enema formulation. Topically-administered transdermalpatches are also included in this invention.

The pharmaceutical compositions of this invention may be administered bynasal aerosol or inhalation. Such compositions are prepared according totechniques well-known in the art of pharmaceutical formulation and maybe prepared as solutions in saline, employing benzyl alcohol or othersuitable preservatives, absorption promoters to enhance bioavailability,fluorocarbons, and/or other solubilizing or dispersing agents known inthe art.

According to another embodiment, compounds of formula (I), or apharmaceutically acceptable salt thereof, may also be delivered byimplantation (e.g., surgically), such as with an implantable orindwelling device. An implantable or indwelling device may be designedto reside either permanently or temporarily in a subject. Examples ofimplantable and indwelling devices include, but are not limited to,contact lenses, central venous catheters and needleless connectors,endotracheal tubes, intrauterine devices, mechanical heart valves,pacemakers, peritoneal dialysis catheters, prosthetic joints, such aship and knee replacements, tympanostomy tubes, urinary catheters, voiceprostheses, stents, delivery pumps, vascular filters and implantablecontrol release compositions. Biofilms can be detrimental to the healthof patients with an implantable or indwelling medical device becausethey introduce an artificial substratum into the body and can causepersistent infections. Thus, providing compounds of formula (I), or apharmaceutically acceptable salt thereof, in or on the implantable orindwelling device can prevent or reduce the production of a biofilm. Inaddition, implantable or indwelling devices may be used as a depot orreservoir of compounds of formula (I), or a pharmaceutically acceptablesalt thereof. Any implantable or indwelling device can be used todeliver compounds of formula (I), or a pharmaceutically acceptable saltthereof, provided that a) the device, compounds of formula (I), or apharmaceutically acceptable salt thereof, and any pharmaceuticalcomposition including compounds of formula (I), or a pharmaceuticallyacceptable salt thereof, are biocompatible, and b) that the device candeliver or release an effective amount of compounds of formula (I), or apharmaceutically acceptable salt thereof, to confer a therapeutic effecton the treated patient.

Delivery of therapeutic agents via implantable or indwelling devices isknown in the art. See for example, “Recent Developments in CoatedStents” by Hofma et al. published in Current Interventional CardiologyReports 2001, 3:28-36, the entire contents of which, includingreferences cited therein, incorporated herein by reference. Otherdescriptions of implantable devices can be found in U.S. Pat. Nos.6,569,195 and 6,322,847; and U.S. Patent Application Numbers2004/0044405, 2004/0018228, 2003/0229390, 2003/0225450, 2003/0216699 and2003/0204168, each of which is incorporated herein by reference in itsentirety.

In some embodiments, the implantable device is a stent. In one specificembodiment, a stent can include interlocked meshed cables. Each cablecan include metal wires for structural support and polymeric wires fordelivering the therapeutic agent. The polymeric wire can be dosed byimmersing the polymer in a solution of the therapeutic agent.Alternatively, the therapeutic agent can be embedded in the polymericwire during the formation of the wire from polymeric precursorsolutions.

In other embodiments, implantable or indwelling devices can be coatedwith polymeric coatings that include the therapeutic agent. Thepolymeric coating can be designed to control the release rate of thetherapeutic agent. Controlled release of therapeutic agents can utilizevarious technologies. Devices are known that have a monolithic layer orcoating incorporating a heterogeneous solution and/or dispersion of anactive agent in a polymeric substance, where the diffusion of the agentis rate limiting, as the agent diffuses through the polymer to thepolymer-fluid interface and is released into the surrounding fluid. Insome devices, a soluble substance is also dissolved or dispersed in thepolymeric material, such that additional pores or channels are leftafter the material dissolves. A matrix device is generally diffusionlimited as well, but with the channels or other internal geometry of thedevice also playing a role in releasing the agent to the fluid. Thechannels can be pre-existing channels or channels left behind byreleased agent or other soluble substances.

Erodible or degradable devices typically have the active agentphysically immobilized in the polymer. The active agent can be dissolvedand/or dispersed throughout the polymeric material. The polymericmaterial is often hydrolytically degraded over time through hydrolysisof labile bonds, allowing the polymer to erode into the fluid, releasingthe active agent into the fluid. Hydrophilic polymers have a generallyfaster rate of erosion relative to hydrophobic polymers. Hydrophobicpolymers are believed to have almost purely surface diffusion of activeagent, having erosion from the surface inwards. Hydrophilic polymers arebelieved to allow water to penetrate the surface of the polymer,allowing hydrolysis of labile bonds beneath the surface, which can leadto homogeneous or bulk erosion of polymer.

The implantable or indwelling device coating can include a blend ofpolymers each having a different release rate of the therapeutic agent.For instance, the coating can include a polylactic acid/polyethyleneoxide (PLA-PEO) copolymer and a polylactic acid/polycaprolactone(PLA-PCL) copolymer. The polylactic acid/polyethylene oxide (PLA-PEO)copolymer can exhibit a higher release rate of therapeutic agentrelative to the polylactic acid/polycaprolactone (PLA-PCL) copolymer.The relative amounts and dosage rates of therapeutic agent deliveredover time can be controlled by controlling the relative amounts of thefaster releasing polymers relative to the slower releasing polymers. Forhigher initial release rates the proportion of faster releasing polymercan be increased relative to the slower releasing polymer. If most ofthe dosage is desired to be released over a long time period, most ofthe polymer can be the slower releasing polymer. The device can becoated by spraying the device with a solution or dispersion of polymer,active agent, and solvent. The solvent can be evaporated, leaving acoating of polymer and active agent. The active agent can be dissolvedand/or dispersed in the polymer. In some embodiments, the co-polymerscan be extruded over the device.

Dosage levels of between about 0.01 and about 100 mg/kg body weight perday, preferably between 0.5 and about 75 mg/kg body weight per day andmost preferably between about 1 and 50 mg/kg body weight per day of theactive ingredient compound are useful in a monotherapy for theprevention and treatment of bacterial infections.

Typically, the pharmaceutical compositions of this invention will beadministered from about 1 to 5 times per day or alternatively, as acontinuous infusion. Alternatively, the compositions of the presentinvention may be administered in a pulsatile formulation. Suchadministration can be used as a chronic or acute therapy. The amount ofactive ingredient that may be combined with the carrier materials toproduce a single dosage form will vary depending upon the host treatedand the particular mode of administration. A typical preparation willcontain from about 5% to about 95% active compound (w/w). Preferably,such preparations contain from about 20% to about 80% active compound.

When the compositions of this invention comprise a combination of acompound of formula (I), or a pharmaceutically acceptable salt thereof,and one or more additional therapeutic or prophylactic agents, both thecompound and the additional agent should be present at dosage levels ofbetween about 10% to 80% of the dosage normally administered in amonotherapy regime.

Upon improvement of a patient's condition, a maintenance dose of acompound, composition or combination of this invention may beadministered, if necessary. Subsequently, the dosage or frequency ofadministration, or both, may be reduced, as a function of the symptoms,to a level at which the improved condition is retained when the symptomshave been alleviated to the desired level, treatment should cease.Patients may, however, require intermittent treatment on a long-termbasis upon any recurrence or disease symptoms.

As the skilled artisan will appreciate, lower or higher doses than thoserecited above may be required. Specific dosage and treatment regimensfor any particular patient will depend upon a variety of factors,including the activity of the specific compound employed, the age, bodyweight, general health status, sex, diet, time of administration, rateof excretion, drug combination, the severity and course of the disease,and the patient's disposition to the disease and the judgment of thetreating physician.

According to another embodiment, the invention provides methods fortreating or preventing a bacterial infection, or disease state,comprising the step of administering to a patient any compound,pharmaceutical composition, or combination described herein. The term“patient”, as used herein, means an animal, preferably a mammal, andmost preferably a human.

The compounds of this invention are also useful as commercial reagentswhich effectively bind to the gyrase B and/or topoisomerase IV enzymes.As commercial reagents, the compounds of this invention, and theirderivatives, may be used to block gyrase B and/or topoisomerase IVactivity in biochemical or cellular assays for bacterial gyrase B and/ortopoisomerase IV or their homologs or may be derivatized to bind to astable resin as a tethered substrate for affinity chromatographyapplications. These and other uses which characterize commercial gyraseB and/or topoisomerase IV inhibitors will be evident to those ofordinary skill in the art.

In order that this invention be more fully understood, the followingschemes and examples are set forth. These examples are for the purposeof illustration only and are not to be construed as limiting the scopeof the invention in any way.

The following definitions describe terms and abbreviations used herein:

-   Ac acetyl-   Bu butyl-   Et ethyl-   Ph phenyl-   Me methyl-   THF tetrahydrofuran-   DCM dichloromethane-   CH₂Cl₂ dichloromethane-   EtOAc ethyl acetate-   CH₃CN acetonitrile-   EtOH ethanol-   Et₂O diethyl ether-   MeOH methanol-   MTBE methyl tert-butyl ether-   DMF N,N-dimethylformamide-   DMA N,N-dimethylacetamide-   DMSO dimethyl sulfoxide-   HOAc acetic acid-   TEA triethylamine-   TFA trifluoroacetic acid-   TFAA trifluoroacetic anhydride-   Et₃N triethylamine-   DIPEA diisopropylethylamine-   DIEA diisopropylethylamine-   K₂CO₃ potassium carbonate-   Na₂CO₃ sodium carbonate-   Na₂S₂O₃ sodium thiosulfate-   Cs₂CO₃ cesium carbonate-   NaHCO₃ sodium bicarbonate-   NaOH sodium hydroxide-   Na₂SO₄ sodium sulfate-   MgSO₄, magnesium sulfate-   K₃PO₄ potassium phosphate-   NH₄Cl ammonium chloride-   LC/MS liquid chromatography/mass spectra-   GCMS gas chromatography mass spectra-   HPLC high performance liquid chromatography-   GC gas chromatography-   LC liquid chromatography-   IC ion chromatography-   IM intramuscular-   CFU/cfu colony forming units-   MIC minimum inhibitory concentration-   Hr or h hours-   atm atmospheres-   rt or RT room temperature-   TLC thin layer chromatography-   HCl hydrochloric acid-   H₂O water-   EtNCO ethyl isocyanate-   Pd/C palladium on carbon-   NaOAc sodium acetate-   H₂SO₄ sulfuric acid-   N₂ nitrogen gas-   H₂ hydrogen gas-   n-BuLi n-butyl lithium-   DI de-ionized-   Pd(OAc)₂ palladium(II)acetate-   PPh₃ triphenylphosphine-   i-PrOH isopropyl alcohol-   NBS N-bromosuccinimide-   Pd[(Ph₃)P]₄ tetrakis(triphenylphosphine)palladium(0)-   PTFE polytetrafluoroethylene-   rpm revolutions per minute-   SM starting material-   Equiv. equivalents-   ¹H-NMR proton nuclear magnetic resonance    Synthesis of the Compounds

EXAMPLES The 6-Fluoro Benzimidazolyl Urea Compound Synthesis of(R)-1-ethyl-3-(6-fluoro-5-(2-(2-hydroxypropan-2-yl)pyrimidin-5-yl)-7-(tetrahydrofuran-2-yl)-1H-benzo[d]imidazol-2-yl)urea

Scheme 3 provides a method for preparing the 6-fluoro benzoimidazolylurea compound.

Example 1.a Preparation of 2-(2-fluoro-6-nitro-phenyl)-2,3-dihydrofuran(15A) and 2-(2-fluoro-6-nitro-phenyl)-2,5-dihydrofuran (15B)

2-Bromo-1-fluoro-3-nitro-benzene (14) (200.3 g, 98%, 892.3 mmol, BoscheF6657), 1,4-dioxane (981.5 mL, Sigma-Aldrich 360481), and2,3-dihydrofuran (2) (341.1 mL, 99%, 4.462 mol, Aldrich 200018) werecharged in a reaction flask, followed by N,N-diisopropylethylamine(155.4 mL, 892.3 mmol, Sigma-Aldrich 550043) andbromo(tri-tert-butylphosphine)palladium(I) dimer (6.936 g, 8.923 mmol,Johnson Matthey C4099). The mixture was stirred at reflux for 2 hrs(HPLC showed 98% consumption of starting arylbromide). The reactionmixture was allowed to cool; the precipitate was removed by filtration,rinsed with EtOAc, and the filtrate concentrated in vacuo to a darkreddish brown semi-solid oil. The semi-solid oil was dissolved inCH₂Cl₂, eluted through a plug of silica with CH₂Cl₂, and concentrated invacuo giving a mixture of 15A and 15B as a dark amber oil (291.3 g). Thecrude product was carried forward without further purification. Themajor product was 2-(2-fluoro-6-nitro-phenyl)-2,3-dihydrofuran (15A)(96%): LCMS (C18 column eluting with 10-90% CH₃CN/water gradient over 5minutes with formic acid modifier) M+1: 210.23 (3.13 min); ¹H NMR (300MHz, CDCl₃) δ 7.54 (dt, J=8.0, 1.2 Hz, 1H), 7.43 (td, J=8.2, 5.2 Hz,1H), 7.32 (ddd, J=9.7, 8.3, 1.3 Hz, 1H), 6.33 (dd, J=4.9, 2.4 Hz, 1H),5.80 (t, J=10.9 Hz, 1H), 5.06 (q, J=2.4 Hz, 1H), 3.18-3.07 (m, 1H),2.94-2.82 (m, 1H) ppm. The minor product was2-(2-fluoro-6-nitro-phenyl)-2,5-dihydrofuran (15B) (4%): GCMS (AgilentHP-5MS 30 m×250 μm×0.25 μm column heating at 60° C. for 2 min to 300° C.over 15 min with a 1 mL/min flow rate) M+1: 210 (11.95 min). ¹H NMR (300MHz, CDCl₃) δ 7.47 (d, J=8.0 Hz, 1H), 7.43-7.34 (m, 1H), 7.30-7.23 (m,1H), 6.21-6.15 (m, 1H), 6.11-6.06 (m, 1H), 5.97-5.91 (m, 1H), 4.89-4.73(m, 2H) ppm.

Example 1.b Preparation of 3-fluoro-2-tetrahydrofuran-2-yl-aniline (16)

5% Palladium on carbon (37.3 g, 50% wet, 8.76 mmol, Aldrich 330116) wasplaced in a Parr bottle under nitrogen, followed by MeOH (70 mL,JT-Baker 909333). The crude mixture of2-(2-fluoro-6-nitro-phenyl)-2,3-dihydrofuran and2-(2-fluoro-6-nitro-phenyl)-2,5-dihydrofuran (15A&15B) (186.6 g, 892.1mmol) dissolved in MeOH (117 mL) was added to the Parr bottle, followedby NEt₃ (124.3 mL, 892.1 mmol, Sigma-Aldrich 471283). The bottle wasplaced on a Parr shaker and saturated with H₂. After adding 45 psi H₂,the reaction mixture was shaken until consumption of the startingmaterial was complete (HPLC and LCMS showed complete reaction). Thereaction mixture was purged with nitrogen, filtered through Celite™ andrinsed with EtOAc. The filtrate was concentrated on a rotary evaporatorgiving brown oil, which was dissolved in Et₂O and washed with water(2×). The ether phase was extracted with aqueous 1 N HCl (5×250 mL),which was washed with Et₂O (3×) and then basified with aqueous 6 N NaOHto pH 12-14. The basic aqueous phase was extracted with dichloromethane(CH₂Cl₂, 4×), and the combined organic extract was washed with saturatedaqueous NH₄Cl, dried over MgSO₄, and filtered through a pad of silicaeluting with CH₂Cl₂ to 25% EtOAc/hexane. The desired filtrate wasconcentrated under reduced pressure giving 16 as a light brown oil(121.8 g, 84% GCMS plus NMR purity). GCMS (Agilent HP-5MS 30 m×250μm×0.25 μm column heating at 60° C. for 2 min to 300° C. over 15 minwith a 1 mL/min flow rate) M+1: 182.0 (11.44 min). LCMS (C18 columneluting with 10-90% CH₃CN/water gradient over 5 minutes with formic acidmodifier) M+1: 182.10 (2.61 min). ¹H NMR (300 MHz, CDCl₃) δ 6.97 (td,J=8.1, 6.3 Hz, 1H), 6.43-6.35 (m, 2H), 5.21-5.13 (m, 1H), 4.54 (s, 2H),4.16-4.07 (m, 1H), 3.90-3.81 (m, 1H), 2.23-2.00 (m, 4H) ppm. Additionalcrops were obtained as follows: the combined ether phase was washed withsaturated aqueous NaHCO₃, brine, dried over Na₂SO₄, decanted, andconcentrated under reduced pressure. The oil was vacuum distilled (ca.15 ton) collecting the distillate at 101-108° C. To a stirring solutionof the distilled oil in EtOH (1 volume) at 2° C. was slowly added 5 MHCl (1 eq) in iPrOH. The resulting suspension was brought to roomtemperature, diluted with EtOAc (3 volumes, vol/vol), and stirred for 2hrs. A white solid was collected by filtration, washed with EtOAc, anddried under reduced pressure giving a second crop of product as the HClsalt. The mother liquor was concentrated to a slurry, diluted with EtOAcand the solid collected by filtration, washed with EtOAc, and dried invacuo giving the HCl salt as a third crop of the product. LCMS (C18column eluting with 10-90% CH₃CN/water gradient over 5 minutes withformic acid modifier) M+1: 182.10 (2.58 min). ¹H NMR (300 MHz, CDCl₃) δ10.73 (br.s, 3H), 7.66 (d, J=8.1 Hz, 1H), 7.33 (td, J=8.2, 5.9 Hz, 1H),7.13-7.05 (m, 1H), 5.26 (dd, J=9.0, 6.5 Hz, 1H), 4.38-4.28 (m, 1H),4.00-3.91 (m, 1H), 2.59-2.46 (m, 1H), 2.30-1.95 (m, 3H) ppm. The overallyield from the three crops was 76%.

Example 1.c Preparation of4-bromo-3-fluoro-2-tetrahydrofuran-2-yl-aniline (17)

To a stirring solution of 3-fluoro-2-tetrahydrofuran-2-yl-aniline (16)(131.9 g, 92%, 669.7 mmol) in methyl tert-butyl ether (1.456 L) andacetonitrile (485 mL) cooled to −20° C. was added N-bromosuccinimide(120.4 g, 99%, 669.7 mmol, Aldrich B81255) in 3 portions maintaining areaction temperature below about −15° C. After complete addition,stirring was continued at −15 to −10° C. for 30 minutes. ¹H NMR of aworked-up aliquot showed 96% consumption of starting aniline. Another4.82 g NBS was added to the reaction mixture and stirred at −10° C. foradditional 30 minutes. Aqueous 1 N Na₂S₂O₃ (670 mL) was added to thereaction mixture. The cold bath was removed, the mixture stirred for 20minutes, then diluted with EtOAc. The layers were separated. The organicphase was washed with saturated aqueous NaHCO₃ (2×), water, and brine,dried over Na₂SO₄, decanted, and concentrated under reduced pressuregiving a dark amber oil. The residue was diluted with hexane and elutedthrough a short plug of silica with 25% EtOAc/hexane to 50%EtOAc/hexane. The desired filtrate was concentrated in vacuo giving 17as a dark amber oil (182.9 g, 90% yield; 86% NMR purity). LCMS (C18column eluting with 10-90% AcN/water gradient over 5 minutes with formicacid modifier) M+1: 260.12 (3.20 min). ¹H NMR (300 MHz, CDCl₃) δ 7.15(dd, J=8.6, 7.6 Hz, 1H), 6.30 (dd, J=8.7, 1.3 Hz, 1H), 5.19-5.12 (m,1H), 4.58 (s, 2H), 4.16-4.07 (m, 1H), 3.90-3.81 (m, 1H), 2.23-1.99 (m,4H) ppm.

Example 1.d Preparation ofN-(4-bromo-3-fluoro-6-nitro-2-tetrahydrofuran-2-yl-phenyl)-2,2,2-trifluoro-acetamide(18)

To trifluoroacetic anhydride (565.3 mL, 4.067 mol, Sigma-Aldrich 106232)stirring at 2° C. was slowly added neat4-bromo-3-fluoro-2-tetrahydrofuran-2-yl-aniline (17) (123.0 g, 86%,406.7 mmol) as a thick oil via addition funnel over about 20 minutes(reaction temperature rose to 13° C.). The remaining oil was rinsed intothe reaction mixture with anhydrous THF (35 mL). The cold bath wasremoved and the reaction was heated to 35° C., followed by portion-wiseaddition of NH₄NO₃ (4.88 g×20 portions, 1.22 mol, Sigma-Aldrich A7455)over 2.5 hrs maintaining the reaction temperature between 30 and 41° C.using an ice-water bath only as needed to control the exotherm. Aftercomplete addition the reaction mixture was stirred for another 10minutes (HPLC showed reaction 99% complete). It was slowly poured intocrushed ice (1.23 kg) and stirred for 1 hr to allow formation of afilterable solid precipitate, which was collected and washed with water,sparingly with saturated aqueous NaHCO₃, and water again (to pH 7). Theproduct was dried in a convection oven overnight at 40° C. and thenunder reduced pressure in an oven at 50° C. overnight giving 18 as abeige solid (152.5 g, 90% yield; 96% HPLC purity). LCMS (C18 columneluting with 10-90% CH₃CN/water gradient over 5 minutes with formic acidmodifier) M+1: 401.30 (3.41 min). ¹H NMR (300 MHz, CDCl₃) δ 10.56 (s,1H), 8.19 (d, J=6.6 Hz, 1H), 5.22 (dd, J=10.3, 6.4 Hz, 1H), 4.22 (dd,J=15.8, 7.2 Hz, 1H), 3.99 (dd, J=16.1, 7.5 Hz, 1H), 2.50-2.38 (m, 1H),2.22-2.11 (m, 2H), 1.86-1.71 (m, 1H) ppm.

Example 1.e Preparation of4-bromo-3-fluoro-6-nitro-2-tetrahydrofuran-2-yl-aniline (19)

A reaction flask was charged withN-(4-bromo-3-fluoro-6-nitro-2-tetrahydrofuran-2-yl-phenyl)-2,2,2-trifluoro-acetamide(18) (242.3 g, 604.1 mmol), 1,4-dioxane (1.212 L), and aqueous 2 Msulfuric acid (362.4 mL, 724.9 mmol), and stirred at reflux for 5 days(HPLC showed 98% conversion). The reaction mixture was allowed to cool,diluted with EtOAc, neutralized with saturated aqueous NaHCO₃, separatedthe layers, and re-extracted the aqueous phase with EtOAc (2×). Thecombined organic phase was washed with brine (2×), dried over MgSO₄,filtered and concentrated in vacuo giving 19 as a greenish brown solid(181.7 g, 94% yield; 95% HPLC purity). The product was carried to thenext step without further purification. LCMS (C18 column eluting with10-90% CH₃CN/water gradient over 5 minutes with formic acid modifier)M+1: 305.20 (3.63 min). ¹H NMR (300 MHz, CDCl₃) δ 8.35 (d, J=7.3 Hz,1H), 7.45 (s, 2H), 5.23-5.16 (m, 1H), 4.23-4.14 (m, 1H), 3.93-3.84 (m,1H), 2.31-1.96 (m, 4H) ppm.

Example 1.f Preparation of2-[5-(4-amino-2-fluoro-5-nitro-3-tetrahydrofuran-2-yl-phenyl)pyrimidin-2-yl]propan-2-ol(20)

To a stirring solution of4-bromo-3-fluoro-6-nitro-2-tetrahydrofuran-2-yl-aniline (19) (525.0 g,1.721 mol, Bridge Organics Co.) in 1,4-dioxane (4.20 L, Sigma-Aldrich360481) was added a 1.2 M aqueous solution of NaHCO₃ (4.302 L, 5.163mol). A stream of nitrogen was bubbled through the stirring mixture for2 hrs, followed by addition of2-[5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidin-2-yl]propan-2-ol(7) (545.4 g, 2.065 mol, Bridge Organics Co.) and1,1′-bis(diphenylphosphino)ferrocene dichloropalladium dichloromethaneadduct (42.16 g, 51.63 mmol, Strem 460450). The reaction mixture wasstirred at reflux overnight, allowed to cool, diluted with EtOAc (8.4L), and the layers were separated. The organic phase was washed withsaturated aqueous NH₄Cl and then brine. The aqueous phase wasre-extracted with EtOAc (4 L) and washed this organic extract withbrine. The combined organic phase was dried over MgSO₄, filtered througha short plug of Florisil®, eluted with EtOAc, and the filtrateconcentrated on a rotary evaporator giving a dark brown wet solid. Thiswas dissolved in CH₂Cl₂, loaded on a pad of silica gel, eluted withhexane, then 25% EtOAc/hexane, and then 50% EtOAc/hexane. The desiredfiltrate was concentrated on a rotary evaporator to a thick suspension,and the solid was collected by filtration, triturated with MTBE, anddried in vacuo giving 20 as a bright yellow solid (55.8% yield, 90-97%HPLC purity). The filtrate was concentrated and the above purificationwas repeated giving a second crop of 20 as a bright yellow solid (19.7%yield). The filtrate was again concentrated giving a dark brown oil andthis was loaded on a silica column with toluene and minimal CH₂Cl₂. Itwas eluted with EtOAc/hexane (0% to 50%). The desired fractions wereconcentrated to a slurry and diluted with MTBE/hexane. The solid wascollected by filtration and washed with minimal MTBE giving a third cropof 20 as a bright yellow solid (4.9% yield) with an overall yield of 80%from the three crops. LCMS (C18 column eluting with 10-90% CH₃CN/watergradient over 5 minutes with formic acid modifier) M+1: 363.48 (2.95min). ¹H NMR (300 MHz, CDCl₃) δ 8.84 (d, J=1.6 Hz, 2H), 8.27 (d, J=8.0Hz, 1H), 7.62 (s, 2H), 5.31-5.24 (m, 1H), 4.63 (s, 1H), 4.27-4.18 (m,1H), 3.97-3.87 (m, 1H), 2.33-2.05 (m, 4H), 1.64 (s, 6H) ppm.

Example 1.g Preparation of2-[5-(4,5-diamino-2-fluoro-3-tetrahydrofuran-2-yl-phenyl)pyrimidin-2-yl]propan-2-ol(21)

5% Palladium on carbon (14.21 g, 50% wet, 3.339 mmol, Aldrich 330116)was placed in a Parr bottle under nitrogen, followed by MeOH (242 mL,JT-Baker 909333) and NEt₃ (46.54 mL, 333.9 mmol, Sigma-Aldrich 471283).2-[5-(4-Amino-2-fluoro-5-nitro-3-tetrahydrofuran-2-yl-phenyl)pyrimidin-2-yl]propan-2-ol(20) (121.0 g, 333.9 mmol) was dissolved in hot THF (360 mL), allowed tocool, added to the reaction mixture, and rinsed the residual amount of20 with another portion of THF (124 mL). The bottle was placed on a Parrshaker and saturated with H₂. After adding 45 psi H₂, the bottle wasshaken until consumption of 20 was complete (HPLC and LCMS showedcomplete reaction). The reaction mixture was purged with nitrogen,filtered through Celite™ and rinsed with EtOAc. It was re-filteredthrough paper (glass microfibre) and the filtrate concentrated in vacuo.The reaction was repeated three more times on the same scale and thebatches were combined giving 21 as a brown solid (447 g, 99% yield; 93%HPLC purity). LCMS (C18 column eluting with 10-90% CH₃CN/water gradientover 5 minutes with formic acid modifier) M+1: 333.46 (1.79 min). ¹H NMR(300 MHz, CDCl₃) δ 8.81 (d, J=1.4 Hz, 2H), 6.69 (d, J=7.3 Hz, 1H),5.27-5.20 (m, 1H), 4.73 (s, 1H), 4.70 (s, 2H), 4.23-4.14 (m, 1H),3.94-3.86 (m, 1H), 3.22 (s, 2H), 2.32-2.22 (m, 1H), 2.18-1.99 (m, 3H),1.63 (s, 6H) ppm.

Example 1.h Preparation of1-ethyl-3-[6-fluoro-5-[2-(1-hydroxy-1-methyl-ethyl)pyrimidin-5-yl]-7-tetrahydrofuran-2-yl-1H-benzimidazol-2-yl]urea(22)

To a stirring suspension of2-[5-(4,5-diamino-2-fluoro-3-tetrahydrofuran-2-yl-phenyl)pyrimidin-2-yl]propan-2-ol(21) (111.3 g, 334.9 mmol) and 1,4-dioxane (556.5 mL, Sigma-Aldrich360481) was added1-ethyl-3-(N-(ethylcarbamoyl)-C-methylsulfanyl-carbonimidoyl)urea (10)(93.36 g, 401.9 mmol, CB Research and Development) followed by a pH 3.5buffer (1.113 L), prepared by dissolving NaOAc trihydrate (158.1 g) in1N aqueous H₂SO₄ (1.100 L). The reaction mixture was stirred at refluxovernight (HPLC showed complete conversion), cooled to room temperature,and poured portion-wise (to minimize frothing) into a stirring solutionof aqueous saturated NaHCO₃ (2.23 L) giving pH 8-9. The resultingmixture was stirred for 30 minutes, the solid was collected byfiltration, washed copiously with water to neutral pH, and then moresparingly with EtOH. The solid was dried under reduced pressure giving22 as an off-white yellowish solid (135.2 g, 94% yield; 99% HPLCpurity). LCMS (C18 column eluting with 10-90% CH₃CN/water gradient over5 minutes with formic acid modifier) M+1: 429.58 (2.03 min). ¹H NMR (300MHz, MeOD) δ 8.95 (d, J=1.6 Hz, 2H), 7.45 (d, J=6.5 Hz, 1H), 5.38 (br.s,1H), 4.27 (dd, J=14.9, 7.1 Hz, 1H), 4.01 (dd, J=15.1, 7.0 Hz, 1H),3.37-3.29 (m, 2H), 2.55 (br.s, 1H), 2.19-2.07 (m, 2H), 2.02-1.82 (br.s,1H), 1.63 (s, 6H), 1.21 (t, J=7.2 Hz, 3H) ppm.

Example 1.i Chiral chromatographic isolation of1-ethyl-3-[6-fluoro-5-[2-(1-hydroxy-1-methyl-ethyl)pyrimidin-5-yl]-7-[(2R)-tetrahydrofuran-2-yl]-1H-benzimidazol-2-yl]urea(23)

A racemic sample of1-ethyl-3-[6-fluoro-5-[2-(1-hydroxy-1-methyl-ethyl)pyrimidin-5-yl]-7-tetrahydrofuran-2-yl-1H-benzimidazol-2-yl]urea(22) (133.60 g) was resolved on a CHIRALPAK® IC® column (by ChiralTechnologies) eluting with CH₂Cl₂/MeOH/TEA (60/40/0.1) at 25° C. givingthe desired enantiomer 23 as an off-white solid (66.8 g, 45% yield;99.8% HPLC purity, 99+% ee). Analytical chiral HPLC retention time was7.7 min (CHIRALPAK® IC® 4.6×250 mm column, 1 mL/min flow rate, 30° C.).The solid was suspended in 2:1 EtOH/Et₂O (5 volumes), stirred for 10minutes, collected by filtration, washed with 2:1 EtOH/Et₂O, and driedunder reduced pressure giving a white solid (60.6 g).

The structure and absolute stereochemistry of 23 were confirmed bysingle-crystal x-ray diffraction analysis. Single crystal diffractiondata was acquired on a Bruker Apex II diffractometer equipped withsealed tube Cu K-alpha source (Cu Kα radiation, y=1.54178 Å) and an ApexII CCD detector. A crystal with dimensions of 0.15×0.15×0.10 mm wasselected, cleaned using mineral oil, mounted on a MicroMount andcentered on a Bruker APEXII system. Three batches of 40 frames separatedin reciprocal space were obtained to provide an orientation matrix andinitial cell parameters. Final cell parameters were obtained and refinedafter data collection was completed based on the full data set. Based onsystematic absences and intensities statistics the structure was solvedand refined in acentric P2₁ space group.

A diffraction data set of reciprocal space was obtained to a resolutionof 0.85 Å using 0.5° steps using 30 s exposures for each frame. Datawere collected at 100 (2) K. Integration of intensities and refinementof cell parameters were accomplished using APEXII software. Observationof the crystal after data collection showed no signs of decomposition.As shown in FIG. 2, there are two symmetry independent molecules in thestructure and both symmetry independent molecules are R isomers.

The data was collected, refined and reduced using the Apex II software.The structure was solved using the SHELXS97 (Sheldrick, 1990);program(s) and the structure refined using the SHELXL97 (Sheldrick,1997) program. The crystal shows monoclinic cell with P2₁ space group.The lattice parameters are a=9.9016(2) Å, b=10.9184(2) Å, c=19.2975(4)Å, β=102.826(1)°. Volume=2034.19(7) Å³.

Example 1.j Preparation of the methanesulfonic acid salt1-ethyl-3-[6-fluoro-5-[2-(1-hydroxy-1-methyl-ethyl)pyrimidin-5-yl]-7-[(2R)-tetrahydrofuran-2-yl]-1H-benzimidazol-2-yl]urea(24)

To a stirring suspension of1-ethyl-3-[6-fluoro-5-[2-(1-hydroxy-1-methyl-ethyl)pyrimidin-5-yl]-7-[(2R)-tetrahydrofuran-2-yl]-1H-benzimidazol-2-yl]urea(23) (15.05 g, 35.13 mmol) in dichloromethane (60 mL, J. T. Baker931533) and absolute ethanol (15 mL, Pharmco-AAPER 111000200) was addedmethanesulfonic acid (2.392 mL, 36.89 mmol, Sigma-Aldrich 471356).Stirred at room temperature until a clear solution was observed. Addedheptane (300 mL) slowly over about 1 hr and collected the solidprecipitate by filtration (using a Whatman qualitative #3 paper on topof a Whatman GF/F glass microfibre paper). Dried under reduced pressurein a vacuum oven (desiccated with calcium sulfate and potassiumhydroxide) overnight at 40° C. giving 24 as a white solid (13.46 g, 99+%HPLC purity, 99+% ee). Analytical chiral HPLC shows one enantiomer withretention time of 8.6 min eluting with CH₂Cl₂/MeOH/TEA (60/40/0.1) on aCHIRALPAK® IC® 4.6×250 mm column with 1 mL/min flow rate at 30° C. Asecond crop of white solid product 24 (4.36 g, 98% HPLC purity, 99+% ee)was obtained from the filtrate. LCMS (C18 column eluting with 10-90%CH₃CN/water gradient over 5 minutes with formic acid modifier) M+1:429.58 (2.03 min). ¹H NMR (300 MHz, MeOD) δ 9.00 (d, J=1.6 Hz, 2H), 7.67(d, J=6.1 Hz, 1H), 5.39 (t, J=7.7 Hz, 1H), 4.30 (dd, J=14.9, 6.9 Hz,1H), 4.03 (dd, J=14.8, 7.7 Hz, 1H), 3.40-3.31 (m, 2H), 2.72 (s, 3H),2.70-2.60 (m, 1H), 2.21-2.08 (m, 2H), 1.98-1.84 (m, 1H), 1.65 (s, 6H),1.22 (t, J=7.2 Hz, 3H) ppm.

Example 1.k Preparation of1-ethyl-3-[6-fluoro-5-[2-(1-hydroxy-1-methyl-ethyl)pyrimidin-5-yl]-7-tetrahydrofuran-2-yl-1H-benzimidazol-2-yl]urea

To a solution of2-[5-(4,5-diamino-2-fluoro-3-tetrahydrofuran-2-yl-phenyl)pyrimidin-2-yl]propan-2-ol(7.220 g, 21.72 mmol) and1-ethyl-3-(N-(ethylcarbamoyl)-C-methylsulfanyl-carbonimidoyl)urea (6.054g, 26.06 mmol, CB Research and Development) in 1,4-dioxane (36.1 mL,Sigma-Aldrich 360481) was added a pH 3.5 buffer (72.2 mL), prepared bydissolving NaOAc trihydrate (5.32 g) in 1N aqueous H₂SO₄ (37 mL). Thereaction mixture was stirred at reflux overnight (HPLC showed completeconversion), cooled to room temperature, and poured portion-wise(frothing) into a stirring solution of aqueous saturated NaHCO₃ (144 mL)giving pH 8-9. This was stirred for 20 minutes, the solid was collectedby filtration, washed copiously with water to neutral pH, and then moresparingly with EtOH. The solid was dried under reduced pressure giving abeige solid (7.90 g, 99% HPLC purity). LCMS (C18 column eluting with10-90% CH₃CN/water gradient over 5 minutes with formic acid modifier)M+1: 429.45 (2.03 min). HPLC retention time was 3.89 min (YMC ODS-AQ150×3.0 mm column eluting with 10-90% CH₃CN/water gradient over 8minutes with 0.1% TFA modifier and 1 mL/min flow rate).

Preparation of Form I Example 1.l Chiral chromatographic isolation of(R)-1-ethyl-3-[6-fluoro-5-[2-(1-hydroxy-1-methyl-ethyl)pyrimidin-5-yl]-7-(tetrahydrofuran-2-yl]-1H-benzimidazol-2-yl]urea

A racemic sample of1-ethyl-3-[6-fluoro-5-[2-(1-hydroxy-1-methyl-ethyl)pyrimidin-5-yl]-7-tetrahydrofuran-2-yl-1H-benzimidazol-2-yl]urea(133.60 g) was resolved on a CHIRALPAK® IC® column (by ChiralTechnologies) eluting with DCM/MeOH/TEA (60/40/0.1) at 25° C. giving thedesired enantiomer as an off-white solid (66.8 g, 99.8% HPLC purity,99+% ee). Analytical chiral HPLC retention time was 7.7 min (CHIRALPAK®IC® 4.6×250 mm column, 1 mL/min flow rate, 30° C.). The solid wassuspended in 2:1 EtOH/Et₂O (5 volumes), stirred for 10 minutes,collected by filtration, washed with 2:1 EtOH/Et₂O, and dried underreduced pressure giving a white solid (60.6 g). ¹H NMR (300 MHz, MeOD) δ8.95 (d, J=1.6 Hz, 2H), 7.45 (d, J=6.5 Hz, 1H), 5.38 (br.s, 1H), 4.27(dd, J=14.9, 7.1 Hz, 1H), 4.01 (dd, J=15.1, 7.0 Hz, 1H), 3.37-3.29 (m,2H), 2.55 (br.s, 1H), 2.19-2.07 (m, 2H), 2.02-1.82 (br.s, 1H), 1.63 (s,6H), 1.21 (t, J=7.2 Hz, 3H) ppm.

Preparation of Form II Example 1.m

To 100 mg of the 6-fluoro benzimidazolyl urea compound I ml of THF wasadded. A stoichiometric amount of HCl was added as a 12M aqueoussolution. Then 4 mL of MTBE was added and the suspension was allowed toequilibrate overnight with stirring at room temperature. It was thenfiltered, and the white solid was dried under vacuum for several hours.

Preparation of Form III Example 1.n

100 mg of 6-fluoro benzimidazolyl urea compound was weighed out anddissolved in 200 mL dichloromethane/methanol 1:1 (v:v) mixture. Thissolution was spray dried on the Buchi B-90 Nano spray dryer (pumpprogram 2) with a condenser attached at spray rates of 100%. Inlettemperature of 101° C. was used with a nitrogen flow of 10 L/min, anitrogen maximum pressure of 10 psi and a maximum CO₂ pressure of 15psi. 55 mg of white powder was recovered.

Spray drying was performed on the Buchi B-90 Nano spray dryer with acondenser attached. A solution of the 6-fluoro benzimidazolyl ureacompound was prepared in a solvent system comprised of CH₂Cl₂:Methanol(1:1) and sprayed according to the parameters listed below.

Preparation of Form IV Example 1.0 Preparation of the methanesulfonicacid salt(R)-1-ethyl-3-[6-fluoro-5-[2-(1-hydroxy-1-methyl-ethyl)pyrimidin-5-yl]-7-(tetrahydrofuran-2-yl)-1H-benzimidazol-2-yl]urea

A stirring suspension of(R)-1-ethyl-3-[6-fluoro-5-[2-(1-hydroxy-1-methyl-ethyl)pyrimidin-5-yl]-7-(tetrahydrofuran-2-yl)-1H-benzimidazol-2-yl]urea(2.530 g, 5.905 mmol) in dichloromethane (22.8 mL, Sigma-Aldrich 270997)and absolute ethanol (2.5 mL) was cooled with an ice-water bath.Methanesulfonic acid (0.402 mL, 6.20 mmol, Sigma-Aldrich 471356) wasadded, removed the cold bath, and stirred at room temperature for 10minutes. The mixture was concentrated on a rotary evaporator at 30° C.to a thick oil, then added slowly to stirring Et₂O, and rinsed theresidual product with CH₂Cl₂ into the ether. The gummy precipitate wasstirred until it broke up into a pasty solid, which was collected byfiltration, washed with Et₂O, and dried under reduced pressure giving anoff-white solid (2.85 g, 99% HPLC purity, 99+% ee). LCMS (C18 columneluting with 10-90% CH₃CN/water gradient over 5 minutes with formic acidmodifier) M+1: 429.51 (2.49 min). HPLC retention time was 3.86 min (YMCODS-AQ 150×3.0 mm column eluting with 10-90% CH₃CN/water gradient over 8minutes with 0.1% TFA modifier and 1 mL/min flow rate). Analyticalchiral HPLC shows one enantiomer with retention time of 7.8 min elutingwith DCM/MeOH/TEA (60/40/0.1) on a CHIRALPAK® IC® 4.6×250 mm column with1 mL/min flow rate at 30° C. ¹H NMR (300 MHz, MeOD) δ 8.99 (d, J=1.6 Hz,2H), 7.67 (d, J=6.1 Hz, 1H), 5.38 (t, J=7.7 Hz, 1H), 4.30 (dd, J=15.0,6.9 Hz, 1H), 4.02 (dd, J=14.8, 7.6 Hz, 1H), 3.38-3.30 (m, 2H), 2.73 (s,3H), 2.70-2.60 (m, 1H), 2.20-2.07 (m, 2H), 1.99-1.84 (m, 1H), 1.64 (s,6H), 1.22 (t, J=7.2 Hz, 3H) ppm.

Example 1.p Stability Data

The mesylate salt of the 6-fluorobenzimidazolyl urea compound was foundto be chemically and physically unstable at 25° C./60% RH at the oneweek time point, and chemically unstable at t=2 weeks when stored at 40°C./ambient.

The free base 6-fluoro benzimidazolyl urea compound was chemically andphysically stable under all storage conditions (25° C./60% RH, 40°C./ambient, and 40° C./75% RH) at the 1 month timepoint. Small changeswere observed in the XRPD pattern, but all were considered to be thesame form as at time zero (t=0).

The hydrochloride salt of the 6-fluoro benzimidazolyl urea compound waschemically and physically stable under all storage conditions (25°C./60% RH, 40° C./ambient, and 40° C./75% RH) at the 1 month timepoint.

Example 2

Enzymology Studies

The enzyme inhibition activities of compounds of this invention may bedetermined in the experiments described below:

DNA Gyrase ATPase Assay

The ATP hydrolysis activity of S. aureus DNA gyrase is measured bycoupling the production of ADP through pyruvate kinase/lactatedehydrogenase to the oxidation of NADH. This method has been describedpreviously (Tamura and Gellert, 1990, J. Biol. Chem., 265, 21342).

ATPase assays are carried out at 30° C. in buffered solutions containing100 mM TRIS pH 7.6, 1.5 mM MgCl₂, 150 mM KCl. The coupling systemcontains final concentrations of 2.5 mM phosphoenol pyruvate, 200 μMnicotinamide adenine dinucleotide (NADH), 1 mM DTT, 30 ug/ml pyruvatekinase, and 10 ug/ml lactate dehydrogenase. The enzyme (90 nM finalconcentration) and a DMSO solution (3% final concentration) of acompound is added. The reaction mixture is allowed to incubate for 10minutes at 30° C. The reaction is initiated by the addition of ATP to afinal concentration of 0.9 mM, and the rate of NADH disappearance ismonitored at 340 nanometers over the course of 10 minutes. The K_(i) andIC₅₀ values are determined from rate versus concentration profiles.

TABLE 3 Inhibition of S. aureus DNA Gyrase Selected Compound K_(i) (nM)Compound 23* 9 *Compound 23 may be prepared as in Example 1.i, above.

DNA Topo IV ATPase Assay

The conversion of ATP to ADP by S. aureus TopoIV enzyme is coupled tothe conversion of NADH to NAD+, and the progress of the reaction ismeasured by the change in absorbance at 340 nm. TopoIV (64 nM) isincubated with the selected compound (3% DMSO final) in buffer for 10minutes at 30° C. The buffer consists of 100 mM Tris 7.5, 1.5 mM MgCl₂,200 mM K•Glutamate, 2.5 mM phosphoenol pyruvate, 0.2 mM NADH, 1 mM DTT,5 μg/mL linearized DNA, 50 μg/mL BSA, 30 μg/mL pyruvate kinase, and 10μg/mL lactate dehyrodgenase (LDH). The reaction is initiated with ATP,and rates are monitored continuously for 20 minutes at 30° C. on aMolecular Devices SpectraMAX plate reader. The inhibition constant, Ki,and the IC₅₀ are determined from plots of rate vs. concentration ofselected compound fit to the Morrison Equation for tight bindinginhibitors.

TABLE 4 Inhibition of S. aureus DNA Topo IV Selected Compound K_(i) (nM)Compound 23 12

Example 3

Susceptibility Testing in Liquid Media

Compounds of this invention were tested for antimicrobial activity bysusceptibility testing in liquid media. Such assays can be performedwithin the guidelines of the latest CLSI document governing suchpractices: “M07-A8 Methods for Dilution Antimicrobial SusceptibilityTests for Bacteria that Grow Aerobically; Approved Standard—EighthEdition (2009)”. Other publications such as “Antibiotics in LaboratoryMedicine” (Edited by V. Lorian, Publishers Williams and Wilkins, 1996)provide essential practical techniques in laboratory antibiotic testing.The specific protocols used were as follows:

Protocol #1: Gyrase MIC Determination of Compounds Using MicrodilutionBroth Method

Materials:

-   Round bottom 96-well microtiter plates (Costar 3788)-   Mueller Hinton II agar plates (MHII; BBL premix)-   Mueller Hinton II liquid broth (MHII; BBL premix)-   BBL Prompt Inoculation System (Fisher B26306)-   Test Reading Mirror (Fisher)-   Agar plates with bacteria streaked to single colonies, freshly    prepared-   Sterile DMSO-   Human serum (U.S. Biologicals S1010-51)-   Laked horse blood (Quad Five 270-100)-   Resazurin 0.01%-   Sprague Dawley Rat serum (U.S. Biologicals 1011-90B or Valley    BioMedical AS3061SD)-   Pooled Mouse serum (Valley BioMedical AS3054)

Strains (Media, Broth and Agar):

-   -   1. Staphylococcus aureus ATCC #29213

a. MHII

b. MHII+50% human serum

c. MHII+50% rat serum

d. MHII+50% mouse serum

-   -   2. Staphylococcus aureus ATCC #29213 GyrB T173I (MHII)    -   3. Staphylococcus aureus, JMI collection strains; see table 9        (MHII)    -   4. Staphylococcus epidermidis, JMI collection strains; see table        9 (MHII)    -   5. Enterococcus faecalis ATCC #29212 (MHII+3% laked horse blood)    -   6. Enterococcus faecium ATCC #49624 (MHII+3% laked horse blood)    -   7. Enterococus faecalis, JMI collection strains; see table 9        (MHII+3% laked horse blood)    -   8. Enterococus faecium, JMI collection strains; see table 9        (MHII+3% laked horse blood)    -   9. Streptococcus pneumoniae ATCC #10015 (MHII+3% laked horse        blood)    -   10. Streptococcus pneumoniae, JMI collection strains; see table        9 (MHII+3% laked horse blood)    -   11. β-haemolytic streptococci, Groups A, B, C, G) JMI collection        strains; see table 9 (MHII+3% laked horse blood)    -   12. Bacillus cereus ATCC 10987 (MHII)    -   13. Bacillus cereus ATCC 14579(MHII)    -   14. Bacillus subtilis ATCC 6638 (MHII)    -   15. Bacillus subtilis (168) ATCC 6051 (MHII)

Inoculum Prep (for all Strains Other than S. aureus+50% Sera):

-   -   1. Using the BBL Prompt kit, picked 5 big or 10 small, well        separated colonies from culture grown on the appropriate agar        medium as indicated above and inoculated 1 mL of sterile saline        provided in the kit.    -   2. Vortexed the wells for ˜30 s to provide a suspension of ˜10⁸        cells/mL. Actual density could be confirmed by plating out        dilutions of this suspension.    -   3. Diluted the suspension 1/100 by transferring 0.15 mL of cells        into 15 mL (˜10⁶ cells/mL) sterile broth (or see below) for each        plate of compounds tested, then swirled to mix. If more than 1        plate of compounds (>8 compounds), including compound 23 or 24,        were tested, volumes were increased accordingly.        -   a. For E. faecalis, E. faecium and S. pneumoniae: 14.1 mL            MHII+0.9 mL laked horse blood was used.    -   4. Used 50 μl cells (˜5×10⁴ cells) to inoculate each microtiter        well containing 50 μl of the drug diluted in broth (see below).

Drug Dilutions, Inoculation, MIC Determination:

-   -   1. All drug/compound stocks were prepared at 12.8 mg/mL        concentration, usually in 100% DMSO.    -   2. Diluted drug/compound stocks to 200× desired final        concentration in 50 μL DMSO. If starting concentration of MICs        was 8 μg/mL final concentration, then required 6.25 μL of        stock+43.75 μA DMSO. Each 200× stock was placed in a separate        row of column 1 of a new 96 well microtiter plate.    -   3. Added 25 μL of DMSO to columns 2-12 of all rows of the        microtiter plate containing 200× compound stocks and serially        diluted 25 μL from column 1 through column 11, changed tips        after each column. i.e. 25 μA compound+25 μA DMSO=2× dilution.        Left “no compound” DMSO well at the end of the series for        control.    -   4. For each strain tested (except S. aureus+50% human serum),        prepared two microtiter plates with 50 μA of MHII broth using a        Matrix pipettor.    -   5. Transferred 0.5 μL of each dilution (w/Matrix auto-pipettor)        to 50 μL of medium/microtiter well prior to the addition of 50        μl of cells. The usual starting concentration of compound was 8        μg/mL after the 1/200 dilution into medium+cells−compound        concentrations decreased in 2× steps across the rows of the        microtiter plate. All MICs were done in duplicate.    -   6. All wells were inoculated with 50 μl of diluted cell        suspension (see above) to a final volume of 100 μl.    -   7. After inoculum was added, mixed each well thoroughly with a        manual multichannel pipettor; same tips were used going from low        to high concentration of drug in the same microtiter plate.    -   8. Plates were incubated at 37° C. for at least 18 hours.    -   9. Plates were viewed with a test reading mirror after 18 hours        and the MIC was recorded as the lowest concentration of drug        where no growth was observed (optical clarity in the well).

Preparation of S. aureus+50% Human Serum, S. aureus+50% Rat Serum or S.aureus+50% Mouse Serum.

-   -   1. Prepared 50% serum media by combining 15 mL of MHII+15 mL        human serum—total 30 mL. Increased volume in 30 mL increments        when more than 1 compound plate was tested.    -   2. Used the same BBL Prompt inoculum of S. aureus ATCC #29213 as        described above, diluted 1/200 by transferring 0.15 mL of cells        into 30 mL (˜5×10⁵ cells/mL) of the 50% human serum media        prepared above and swirled to mix.    -   3. Filled all test wells of the desired number of microtiter        plates with 100 μL cells in 50% serum media.    -   4. Transferred 0.5 μL of each compound dilution (w/Matrix        auto-pipettor) to 100 μL of cells/media. The usual starting        concentration of compound was 8 μg/mL after the 1/200 dilution        into medium+cells−compound concentrations decreased in 2× steps        across the rows of a microtiter plate. All MICs were done in        duplicate.

-   5. Mixed each well thoroughly with a manual multichannel pipettor;    same tips were used going from low to high concentration of drug in    the same microtiter plate.

-   6. Plates were incubated at 37° C. for at least 18 hours. After    incubation, added 25 μL of 0.01% Resazurin to each well and    continued to incubate at 37° C. for at least 1 additional hour or    until the Resazurin color changes.    -   7. Plates were viewed with a test reading mirror and the MIC was        recorded. When using Resazurin, the color of the dye changed        from a dark blue to a bright pink in wells with no growth. The        lowest concentration of drug that turned the dye pink was the        MIC.

Protocol 2: Gyrase MIC Determination of Compounds Against Gram NegativesUsing Microdilution Broth Method

Materials:

-   Round bottom 96-well microtiter plates (Costar 3788)-   Mueller Hinton II agar plates (MHII; BBL premix)-   Mueller Hinton II liquid broth (MHII; BBL premix)-   BBL Prompt Inoculation System (Fisher b26306)-   Test Reading Mirror (Fisher)-   Agar plates with bacteria streaked to single colonies, freshly    prepared-   Sterile DMSO

Strains (MHII Media for all; Broth and Agar):

-   -   1. Escherichia coli ATCC #25922    -   2. Escherichia coli, JMI collection strains, see table 9    -   3. Escherichia coli AG100 WT    -   4. Escherichia coli AG100 tolC    -   5. Acinetobacter baumannii ATCC # BAA-1710    -   6. Acinetobacter baumannii ATCC #19606    -   7. Acinetobacter baumannii, JMI collection strains, see table 9    -   8. Klebsiella pneumoniae ATCC # BAA-1705    -   9. Klebsiella pneumoniae ATCC #700603    -   10. Klebsiella pneumoniae, JMI collection strains, see table 9    -   11. Moraxella catarrhalis ATCC#25238    -   12. Moraxella catarrhalis ATCC#49143    -   13. Moraxella catarrhalis, JMI collection strains, see table 9    -   14. Haemophilus influenzae ATCC 49247    -   15. Haemophilus influenzae (Rd1 KW20) ATCC 51907    -   16. Haemophilus influenzae Rd0894 (AcrA-)    -   17. Haemophilus influenzae, JMI collection strains, see table 9    -   18. Pseudomonas aeruginosa PAO1    -   19. Pseudomonas aeruginosa, JMI collection strains, see table 9    -   20. Proteus mirabilis, JMI collection strains, see table 9    -   21. Enterobacter cloacae, JMI collection strains, see table 9    -   22. Stenotrophomonas maltophilia ATCC BAA-84    -   Stenotrophomonas maltophilia ATCC13637

Inoculum Prep:

-   -   1. Using the BBL Prompt kit, picked 5 big or 10 small, well        separated colonies from cultures grown on agar medium and        inoculated 1 mL sterile saline that came with the kit.    -   2. Vortexed the wells for ˜30 s to give a suspension of ˜10⁸        cells/mL. Actual density could be confirmed by plating out        dilutions of this suspension.    -   3. Diluted the suspension 1/100 by transferring 0.15 mL of cells        into 15 mL (˜10⁶ cells/mL) sterile broth (see below) for each        plate of compounds tested, swirled to mix. If more than 1 plate        of compounds (>8 compounds), including compound 23 or 24, was to        be tested, increased volumes accordingly.    -   4. Used 50 μl cells (˜5×10⁴ cells) to inoculate each microtiter        well containing 50 μl of the drug diluted in broth (see below).

Drug Dilutions, Inoculation, MIC Determination:

-   -   1. All drug/compound stocks were prepared at 12.8 mg/mL        concentration, usually in 100% DMSO.    -   2. Diluted drug/compound stocks to 200× desired final        concentration in 50 μL DMSO. If starting concentration of MICs        was 8 μg/mL final concentration, then required 6.25 μl of        stock+43.75 μL DMSO. Each 200× stock was placed in a separate        row of column 1 of a new 96 well microtiter plate.    -   3. Added 25 μL of DMSO to columns 2-12 of all rows of the        microtiter plate containing 200× compound stocks and serially        diluted 25 μL from column 1 through column 11, changed tips        after each column. i.e. 25 μL compound+25 μL DMSO=2× dilution.        Left “no compound” DMSO well at the end of the series for        control.    -   4. For each strain tested, prepared two microtiter plates with        50 μL of MHII broth using a Matrix pipettor.    -   5. Transferred 0.5 μL of each dilution (w/Matrix auto-pipettor)        to 50 μL of medium/microtiter well prior to the addition of 50        μl of cells. The usual starting concentration of compound was 8        μg/mL after the 1/200 dilution into medium+cells−compound        concentrations decreased in 2× steps across the rows of a        microtiter plate. All MICs were done in duplicate.    -   6. All wells were inoculated with 50 μl of diluted cell        suspension (see above) to a final volume of 100    -   7. After inoculum was added, each well was mixed thoroughly with        a manual multichannel pipettor; same tips were used going from        low to high concentration of drug in the same microtiter plate.    -   8. Plates were incubated at 37° C. for at least 18 hours.    -   9. Plates were viewed with a test reading mirror after 18 hours        and the MIC was recorded as the lowest concentration of drug        where no growth was observed (optical clarity in the well).

Protocol #3: Gyrase MIC Determination of Compounds Using Agar DilutionMethod

Materials:

-   Petri plates 60×15 mm (Thermo Scientific Cat. #12567100)-   Centrifuge tubes, 15 mL (Costar)-   BBL Prompt Inoculation System (Fisher b26306)-   Agar plates with bacteria streaked to single colonies, freshly    prepared Sterile DMSO-   GasPak™ incubation containers (BD Cat. #260672)-   GasPak™ EZ Anaerobe container system sachets (BD Cat. #260678)-   GasPak™ EZ C02 container system sachets (BD Cat. #260679)-   GasPak™ EZ Campy container system sachets (BD Cat. #260680)

Strains:

-   -   1. Clostridium difficile ATCC BAA-1382;    -   2. Clostridium difficile, CMI collection strains, see table 8    -   3. Clostriudium perfringens, CMI collection strains, see table 8    -   4. Bacteroides fragilis and Bacteroides spp., CMI collection        strains, see table 8    -   5. Fusobacterium spp., CMI collection strains, see table 8    -   6. Peptostreptococcus, spp., CMI collections strains, see table        8    -   7. Prevotella spp., CMI collection strains, see table 8    -   8. N. gonorrhoeae ATCC 35541    -   9. N. gonorrhoeae ATCC 49226    -   10. Neisseria gonorrhoeae, JMI collection strains, see table 8    -   11. Neisseria meningitidis, JMI collection strains, see table 8

Media Preparation and Growth Conditions:

-   -   Growth medium recommended for each microbial species was        prepared according to the CLSI publication ‘M11-A7 Methods for        Antimicrobial Susceptibility Testing of Anaerobic Bacteria;        Approved Standard—Seventh Edition (2007)’ with the exception        of N. gonorrhoeae and N. meningitidis for which media was        prepared according to“M07-A8 Methods for Dilution Antimicrobial        Susceptibility Tests for Bacteria that Grow Aerobically;        Approved Standard—Eighth Edition (2009)”.

Plate Pouring:

-   -   1. Prepared 100× drug stocks of each test compound as described        in Table 1. Used a 15 mL centrifuge tube, added 100 uL of each        drug stock to 10 mL of molten agar (cooled to ˜55° C. in water        bath). Mixed by inverting tube 2-3× then pour into individually        labeled 60×15 mm Petri dish.    -   2. Routine test concentrations were: 0.002 ug/mL-16 ug/mL (14        plates).    -   3. Poured 4 drug free plates: 2 as positive control, 2 as        aerobic control.    -   4. Allowed plates to dry. Used same day or stored overnight at        RT or stored up to 3 days at 4° C.        Plates were labeled accordingly for drug concentration and        strain placement.

Growth of Cells Requiring the Maintenance of an Anaerobic Environment:

-   -   1. All work performed with anaerobic bacteria was done as        rapidly as possible; work performed in biosafety cabinets (i.e.,        aerobic environment) was completed in less then 30 minutes        before cells were returned to anaerobic chambers.    -   2. Incubation of anaerobic bacteria was achieved using GasPak™        chambers. The large box style chambers (VWR 90003-636) required        2 anaerobic sachets (VWR 90003-642), while the tall cylinder        style chambers (VWR 90003-602) only required 1 sachet.

Plate Inoculation (Performed in Biosafety Cabinet):

-   -   1. Streaked each strain onto individual agar plates as described        above. Incubated for required time and environmental condition        (i.e. anaerobic, microaerophilic, etc).    -   2. Used direct colony suspension method to suspend loopfuls of        freshly streaked cells into ˜4 mL 0.9% NaCl₂ and vortexed.    -   3. Adjusted suspension to O.D.₆₀₀ 0.05 (5×10e7 cfu/mL). Vortexed        to mix.    -   4. Transferred ˜0.2 mL of adjusted, mixed cultures to a 96 well        plate. When ≦5 strains were tested, all strains were lined        together in a single row. When testing >5 strains, transferred        strains into plate with no more that 5 strains in a single row.        This was necessary to fit on the small plates.    -   5. Used multi-channel pipettor, spotted 0.002 mL of each strain        from prepared 96 well plates onto each MIC test plate. This        resulted in ˜1×10e5 cfu/spot. When testing C. difficile, strains        swarmed when grown, however distance between multi-channel        pipettor spots was far enough such that swarming cells did not        impair assay results.        -   a. Inoculated 2 drug free plates first, while the other 2            drug free plates were inoculated last after the MIC test            plates. The former and latter served as growth and            inoculation controls. Incubated one plate from each set of            drug-free controls under required atmospheric conditions            with MIC plates and one set aerobically to test for            contamination with aerobic bacteria. Aerobic culture was            negative for growth when working with strict anaerobe or            microaerophilic strain. Some growth was visible with N.            gonorrhoeae.    -   6. Allowed inoculum to dry (for as short a time as necessary),        then placed upside down in GasPak with appropriate number of        sachets and incubate.    -   7. Neisseria spp. were incubated at 37° C. in a 5% CO₂        environment for 24 h.

MIC Determination:

Examined the test plates after the correct incubation time and read theMIC endpoint at the concentration where a marked reduction occurred inthe appearance of growth on the test plate as compared to that of growthon the positive control plates.

TABLE 5 Compound dilutions for MIC determination using the agar dilutionmethod. Final Volume Volume Diluent, Intermediate Conc. (uL) added Stockfrom stock DMSO Conc. At 1:100 to 10 mL Step (ug/ml) Source (uL) (uL)**(ug/mL) (ug/mL) agar 1  1,600* Stock 1,600 16 100 2 1,600 Stock 75 75800 8 100 3 1,600 Stock 75 225 400 4 100 4 1,600 Stock 75 525 200 2 1005  200 Step 4 75 75 100 1 100 6  200 Step 4 75 225 50 0.5 100 7  200Step 4 75 525 25 0.25 100 8   25 Step 7 75 75 12.5 0.125 100 9   25 Step7 75 225 6.25 0.06 100 10   25 Step 7 75 525 3.1 0.03 100 11   3 Step 7575 1.6 0.016 100 10 12   3 Step 75 225 0.8 0.008 100 10 13   3 Step 75525 0.4 0.004 100 10 14     0.4 Step 75 75 0.2 0.002 100 13 *1,600 ug/ml= 64 ul (10 mg/ml stock) + 336 ul DMSO; 400 ul total volume to start**compound dissolved and diluted in 100% DMSO

Protocol #4. MIC Determination Procedure for Mycobacterium Species

Materials

-   Round bottom 96-well microtiter plates (Costar 3788) or similar-   Film plate seals (PerkinElmer, TopSeal-A #6005250 or similar)-   Middlebrook 7H10 broth with 0.2% glycerol-   Middlebrook 7H10 agar with 0.2% glycerol-   Middlebrook OADC Enrichment

Inoculum Preparation for M. tuberculosis:

-   -   1. Used prepared frozen M. tuberculosis stock stored at        −70° C. M. tuberculosis was grown in 7H10 broth+10% OADC, then        frozen at a concentration of 100 Klett or 5×10⁷ cfu/ml,    -   2. Prepared a 1:20 dilution by removal of 1 ml of the frozen        stock and added it to 19 ml of 7H10 broth+10% OADC (final        concentration 2.5×10⁶ cfu/ml).    -   3. From this dilution prepared a second 1:20 dilution, removed 1        ml and added it to 19 ml of fresh broth. This was the final        inoculum to add to the 96-well plates.

Inoculum Preparation for M. kansasii, M. avium, M. abscessus andNocardia Spc.:

-   -   1. Used prepared frozen stock of culture or a fresh culture        grown in 7H10 broth at a concentration of 10 Klett or 5×10⁷/ml.    -   2. Prepared a 1:20 dilution by removing 1.0 ml of the culture        stock and added it to 19 ml of 7H10 broth (final concentration        2.5×10⁶ cfu/ml).    -   3. From this dilution prepared a 1:20 dilution, removed 1 ml and        added it to 19 ml of fresh broth (final suspension).

Plate Preparation:

-   -   1. Labeled plates.    -   2. Added 50 μl of 7H10 broth+10% OADC to all wells being        utilized for MIC determination using a multichannel electronic        pipettor.    -   3. Prepared stock solutions of drugs (e.g. 1 mg/ml        concentration) to be tested.

4. Thawed and diluted frozen stock solutions using 7H10 broth+10% OADCto obtain a working solution 4× the maximum concentration tested (e.g.final concentration 32 μg/ml, highest concentration tested was 8 μg/ml).Dilutions were made from the stock solution. To start at a concentrationof 1 μg/ml, the drugs were prepared at 4 μg/ml, so the startingconcentration was 1 μg/ml. Removed 25 μl of the 1 mg/ml stock and addedto 6.2 ml of broth. All dilutions of drugs were done in broth.

-   -   5. Added 50 μl of the 4× working solution to the first well of        the designated row. Continued for all compounds to be tested.        Using a multichannel electronic pipettor, mixed 4× and serial        diluted compounds through the 11th well. Discarded remaining 50        μl. Used the 12th well as the positive control.    -   6. Incubated plates at 37° C. M. tuberculosis for ˜18 days; M.        avium and M. kansasii for ˜7 days; Nocardia and M. abcessus for        ˜4 days; with film seals.    -   7. Read visually and recorded the results. The MIC was recorded        as the lowest concentration of drug where no growth was observed        (optical clarity in the well).

Protocol #5. Protocol for Mycobacterium tuberculosis Serum Shift MICAssay

Materials and Reagents:

-   Costar #3904 Black-sided, flat-bottom 96-well microtiter plates-   Middlebrook 7H9 broth (BD271310) with 0.2% glycerol-   Middlebrook OADC Enrichment-   Fetal Bovine Serum-   Catalase (Sigma C1345)-   Dextrose-   NaCl₂-   BBL Prompt Inoculation System (Fisher b26306)-   Agar plates (Middlebrook 7H11 with 0.2% glycerol and OADC    enrichment) with bacteria streaked to single colonies-   Sterile DMSO

Media Prep:

-   -   1. For serum shifted MICs, three different media were required        which all had a base of 7H9+0.2% glycerol. It was important that        all media and supplements were sterilized prior to MICs.    -   2. Prepared all media below and inoculated as described in next        section. Tested all compounds against Mtb using each media.        -   a. 7H9+0.2% glycerol+10% OADC (“standard” MIC media).        -   b. 7H9+0.2% glycerol+2 g/L dextrose+0.85 g/L NaCl+0.003 g/L            catalase (0% FBS).        -   c. 2×7H9+0.2% glycerol+2 g/L dextrose+0.85 g/L NaCl+0.003            g/L catalase combined with equal volume Fetal Bovine Serum            (50% FBS).

Inoculum prep:

-   -   1. Using BBL Prompt, picked 5-10 well-separated colonies and        inoculated 1 ml sterile saline that came in the kit. Typically        plates were two to three weeks of age when used for this assay        due to the slow growth of this organism in culture.    -   2. Vortexed well, then sonicated in water bath for 30 sec        providing a suspension of ˜10⁸ cells/ml. Actual density could be        confirmed by plating out dilutions of this suspension.    -   3. Prepared inoculum in each of the three media formulations by        diluting the BBL Prompt suspension 1/200 (for example:        transferred 0.2 ml of cells to 40 ml of medium) to obtain a        starting cell density of ˜10⁶ cells/ml.    -   4. Used 100 μl cells (˜5×10⁴ cells) to inoculate each microtiter        well containing 1 μl of drug in DMSO (see below).

Drug Dilutions, Inoculation, MIC Determination:

-   -   1. Control drug stocks Isoniazid and Novobiocin were prepared at        10 mM in 100% DMSO while Ciprofloxacin and Rifampin were        prepared at 1 mM in 50% DMSO and 100% DMSO, respectively.        Prepared dilutions—dispensed 100 μL of the stock solution into        the first column of a 96-well plate. Prepared 11-step, 2-fold        serial dilutions across the row for each compound by        transferring 50 μl from column 1 into 50 μl of DMSO in column 2.        Continued to transfer 50 μL from column 2 through column 11        while mixing and changing tips at each column. Left column 12        with DMSO only as a control.    -   2. Transferred 1 μl of each dilution into an empty microtiter        well prior to the addition of 100 μl of cells. The starting        concentration of Isoniazid and Novobiocin was 100 μM after the        dilution into medium+ cells; the starting concentration of        Ciprofloxacin and Rifampin was 10 μM after the dilution into        medium+ cells. Compound concentrations decreased in 2× steps        moving across the rows of the microtiter plate. All MICs were        done in duplicate at each of the three medium conditions.    -   3. Test sets of compounds were typically at 10 mM and 50 μL        volume.    -   4. Used a multichannel pipettor, removed all of the volume from        each column of the master plate and transferred into the first        column of a new 96-well microtiter plate. Repeated for each        column of compounds on master plate, transferring into column 1        of a new 96-well plate.    -   5. As described above for control compounds, generated 2-fold,        11-point dilutions of each compound using DMSO as diluent. In        all cases, left column 12 as DMSO only for a control. Once all        dilutions were complete, again transferred 1 μl of each dilution        into an empty microtiter well prior to the addition of 100 μl of        cells as done for the control compounds.    -   6. All wells were inoculated with 100 μl of diluted cell        suspension (see above).    -   7. After inoculum addition, mixed plates by gently tapping sides        of plate.    -   8. Plates were incubated in a humidified 37° C. chamber for 9        days.    -   9. At 9 days added 25 μl 0.01% sterile resazurin to each well.        Measured background fluorescence at Excitation 492 nm, Emission        595 nm and returned the plate to the incubator for another 24        hours.    -   10. After 24 hours the fluorescence of each well was measured at        Excitation 492 nm, Emission 595 nm.    -   11. Percent inhibition by a given compound was calculated as        follows: Percent inhibition=100−([well fluorescence-average        background fluorescence]/[DMSO control−average background        fluorescence]×100). MICs were scored for all three medium        conditions as the lowest compound concentration that inhibited        resazurin reduction (‘%-inhibition’) signal 70% at a given        medium condition.

-   Table 6 shows the results of the MIC assay for the mesylate salt of    the benzimidazolyl urea compound of this invention.

-   In Table 6 and in subsequent Tables and Examples, “Compound 24” is    amesylate salt of “Compound 23” and may be prepared according to    Example 1.j, above. This is the same number used to identify said    compound as used in the Examples above.

TABLE 6 MIC Values of Compound 24 Compound Strain/Special ConditionProtocol 24 Staphylococcus aureus 1 0.021 ATCC 29213 Staphylococcusaureus ATCC 1 0.15 29213 with Human Serum Staphylococcus aureus 1 0.18ATCC 29213 with Rat Serum Staphylococcus aureus 1 0.5 ATCC 29213 withMouse Serum Staphylococcus aureus 1 0.3 ATCC 29213 GyrB T173IEnterococcus faecalis ATCC 1 0.028 29212, with Laked Horse BloodEnterococcus faecium ATCC 1 0.11 49624 with Laked Horse BloodEnterococcus faecium ATCC 1 0.11 49624 Streptococcus pneumoniae 1 0.01ATCC 10015, with Laked Horse Blood Bacillus cereus ATCC 10987 1 0.031Bacillus cereus ATCC 14579 1 0.031 Bacillus subtilis ATCC 6638 1 2Bacillus subtilis (168) ATCC 1 4 6051 Clostridium difficile ATCC 3 0.38BAA-1382 Haemophilus influenzae 2 0.5 ATCC 49247 Haemophilus influenzae(Rd1 2 1.3 KW20) ATCC 51907 Haemophilus influenzae 2 0.041 Rd0894(AcrA-) Moraxella catarrhalis ATCC 2 ≦0.016 25238 Moraxella catarrhalisATCC 2 ≦0.016 49143 Neisseria gonorrhoeae ATCC 3 0.42 35541 Neisseriagonorrhoeae 3 1 ATCC 49226 Escherichia coli AG100 WT 2 4 Escherichiacoli AG100 tolC 2 0.063 Escherichia coli ATCC 2 12 25922 Escherichiacoli CHE30 2 8 Escherichia coli CHE30 tolC 2 0.125 Escherichia coliMC4100 2 >16 Escherichia coli MC4100 2 0.25 tolC Klebsiella pneumoniae 216 ATCC 700603 Klebsiella pneumoniae 2 12 ATCC BAA-1705 Acinetobacterbaumannii 2 8 ATCC 19606 Acinetobacter baumannii 2 6 ATCC BAA-1710Pseudomonas aeruginosa 2 >16 PAO1 Pseudomonas aeruginosa 2 0.25 PAO750Stenotrophomonas 2 >8 maltophilia ATCC BAA-84 Stenotrophomonas 2 >8maltophilia ATCC13637 Mycobacterium avium 103 4 0.18 M. avium Far 4 0.23M. avium 3404.4 4 0.23 Nocardia caviae 2497 4 0.125 N. asteroids 2039 41 N. nova 10 4 1 M. kansasii 303 4 0.03 M. kansasii 316 4 0.06 M.kansasii 379 4 <0.015 M. tuberculosis H37Rv 4 0.015 ATCC 25618 M.tuberculosis Erdman 4 0.06 ATCC 35801 M. tuberculosis Erdman 5 0.03 ATCC35801 M. tuberculosis Erdman 5 0.5 ATCC 35801 with Mouse Serum M.abscessus BB2 4 1 M. abscessus MC 6005 4 1 M. abscessus MC 5931 4 0.5 M.abscessus MC 5605 4 1.5 M. abscessus MC 6025 4 0.75 M. abscessus MC 59084 1.5 M. abscessus BB3 4 0.5 M. abscessus BB4 4 2 M. abscessus BB5 4 0.5M. abscessus MC 5922 4 0.25 M. abscessus MC 5960 4 0.5 M. abscessus BB14 2 M. abscessus MC 5812 4 1 M. abscessus MC 5901 4 1 M. abscessus BB6 40.5 M. abscessus BB8 4 0.5 M. abscessus MC 5908 4 1 M. abscessus LT 9494 1 M. abscessus BB10 4 0.015 M. abscessus MC 6142 4 0.5 M. abscessus MC6136 4 0.5 M. abscessus MC 6111 4 0.5 M. abscessus MC 6153 4 1

Table 7 shows the results of the MIC90 assay for selected compounds ofthis invention.

TABLE 7 MIC90 Values of Selected Compounds with Panels of Gram Positive,Gram Negative and Anaerobic Pathogens Number of Compound 24 IsolatesRange MIC90 Organism Tested Protocol (μg/ml) (μg/ml) AerobicGram-positive Staphylococcus aureus 67 1 0.008-0.06 0.03 Staphlococcusepidermidis 35 1 0.008-0.03 0.03 Enterococcus faecalis 34 1 0.015-0.120.06 Enterococcus faecium 33 1 0.003-0.25 0.12 Streptococcus pneumoniae67 1 0.008-0.03 0.015 β-haemolytic streptococci 28 1 0.015-0.12 0.12(Groups A, B, C and G) Aerobic Gram-negative Haemophilus influenzae 55 20.06-2   1 Moraxella catarrhalis 26 2 ≦0.004-0.03  0.03 Acinetobacterbaumannii 12 2  4->8 >8 Pseudomonas aeruginosa 12 2  >8->8 >8Escherichia coli 12 2  2->8 >8 Klebsiella pneumoniae 12 2  2->8 >8Proteus mirabilis 12 2  4->8 >8 Enterobacter cloacae 12 2  >8->8 >8Neisseria gonorrhoeae 13 3  0.12-0.25 0.25 Neisseria meningitidis 12 30.008-0.06 0.03 Anaerobes Bacteroides and 26 3 0.12-16 16 Parabacterspp. Bacteroides fragilis 25 3  1-16 16 Clostridium difficile 16 30.06-4   0.25 Clostridium perfringens 12 3 0.12-0.5 0.5 Fusobacteriumspp. 16 3 0.015->16  >16 Peptostreptococcus spp. 11 3  0.03->16 >16Prevotella spp. 13 3 0.06-16  16

In Table 8 below, the term “CMI” stands for The Clinical Microbiology

Institute located in Wilsonville, Oreg.

TABLE 8 Panels of Anaerobic Organism Used to Generate MIC90 Data CMI#ORGANISM A2380 B. fragilis A2381 B. fragilis A2382 B. fragilis A2486 B.fragilis A2487 B. fragilis A2489 B. fragilis A2527 B. fragilis A2529 B.fragilis A2562 B. fragilis A2627 B. fragilis A2802 B. fragilis A2803 B.fragilis A2804 B. fragilis A2805 B. fragilis A2806 B. fragilis A2807 B.fragilis A2808 B. fragilis A2809 B. fragilis A2810 B. fragilis A2811 B.fragilis A2812 B. fragilis A2813 B. fragilis A2814 B. fragilis A2460 B.thetaiotaomicron A2462 B. thetaiotaomicron A2463 B. thetaiotaomicronA2464 B. thetaiotaomicron A2536 B. thetaiotaomicron A2591 B. uniformisA2604 B. vulgatus A2606 B. vulgatus A2613 B. ovatus A2616 B. ovatusA2815 Bacteroides tectum A2816 B. ureolyticus A2817 Bacteroidescapillosus A2818 B. ureolyticus A2824 Parabacter distasonis A2825 B.ovatus A2826 B. uniformis A2827 B. uniformis A2828 B. vulgatus A2829 B.vulgatus A2830 B. ovatus A2831 B. thetaiotaomicron A2832 Parabacterdistasonis A2833 B. thetaiotaomicron A2767 C. difficile A2768 C.difficile A2769 C. difficile A2770 C. difficile A2771 C. difficile A2772C. difficile A2773 C. difficile A2774 C. difficile A2775 C. difficileA2776 C. difficile A2777 C. difficile A2778 C. difficile A2779 C.difficile A2780 C. difficile A2140 C. perfringens A2203 C. perfringensA2204 C. perfringens A2227 C. perfringens A2228 C. perfringens A2229 C.perfringens A2315 C. perfringens A2332 C. perfringens A2333 C.perfringens A2334 C. perfringens A2389 C. perfringens A2390 C.perfringens A864 F. necrophorum A871 F. nucleatum A1667 F. necrophorumA1666 F. necrophorum A2249 F. nucleatum A2716 Fusobacterium speciesA2717 Fusobacterium species A2719 Fusobacterium species A2721Fusobacterium species A2722 Fusobacterium species A2710 Fusobacteriumspecies A2711 Fusobacterium species A2712 Fusobacterium species A2713Fusobacterium species A2714 Fusobacterium species A2715 Fusobacteriumspecies A1594 Peptostreptococcus anaerobius A2158 Peptostreptococcusmagnus A2168 Peptostreptococcus anaerobius A2170 Peptostreptococcusmagnus A2171 Peptostreptococcus magnus A2575 Peptostreptococcus spp.A2579 Peptostreptococcus asaccharolyticus A2580 Peptostreptococcusasaccharolyticus A2614 Peptostreptococcus asaccharolyticus A2620Peptostreptococcus asaccharolyticus A2629 Peptostreptococcus spp. A2739Prevotella denticola A2752 Prevotella bivia A2753 Prevotella intermediaA2754 Prevotella intermedia A2756 Prevotella bivia A2759 Prevotellabivia A2760 Prevotella denticola A2761 Prevotella intermedia A2762Prevotella melaninogenica A2765 Prevotella melaninogenica A2766Prevotella melaninogenica A2821 Prevotella bivia A2822 Prevotella biviaQCBF B. fragilis QCBT B. thetaiotaomicron QCCD C. difficile QCBF B.fragilis QCBT B. thetaiotaomicron QCCD C. difficile

In Table 9 below, the term “JMI” stands for The Jones MicrobiologyInstitute located in North Liberty, Iowa.

TABLE 9 Panels of Gram Positive and Gram Negative Organism Used toGenerate MIC90 Data JMI Organism JMI Isolate # Code Organism 394 ACBAcinetobacter baumannii 2166 ACB Acinetobacter baumannii 3060 ACBAcinetobacter baumannii 3170 ACB Acinetobacter baumannii 9328 ACBAcinetobacter baumannii 9922 ACB Acinetobacter baumannii 13618 ACBAcinetobacter baumannii 14308 ACB Acinetobacter baumannii 17086 ACBAcinetobacter baumannii 17176 ACB Acinetobacter baumannii 30554 ACBAcinetobacter baumannii 32007 ACB Acinetobacter baumannii 1192 ECLEnterobacter cloacae 3096 ECL Enterobacter cloacae 5534 ECL Enterobactercloacae 6487 ECL Enterobacter cloacae 9592 ECL Enterobacter cloacae11680 ECL Enterobacter cloacae 12573 ECL Enterobacter cloacae 12735 ECLEnterobacter cloacae 13057 ECL Enterobacter cloacae 18048 ECLEnterobacter cloacae 25173 ECL Enterobacter cloacae 29443 ECLEnterobacter cloacae 44 EF Enterococcus faecalis 355 EF Enterococcusfaecalis 886 EF Enterococcus faecalis 955 EF Enterococcus faecalis 1000EF Enterococcus faecalis 1053 EF Enterococcus faecalis 1142 EFEnterococcus faecalis 1325 EF Enterococcus faecalis 1446 EF Enterococcusfaecalis 2014 EF Enterococcus faecalis 2103 EF Enterococcus faecalis2255 EF Enterococcus faecalis 2978 EF Enterococcus faecalis 2986 EFEnterococcus faecalis 5027 EF Enterococcus faecalis 5270 EF Enterococcusfaecalis 5874 EF Enterococcus faecalis 7430 EF Enterococcus faecalis7904 EF Enterococcus faecalis 8092 EF Enterococcus faecalis 8691 EFEnterococcus faecalis 9090 EF Enterococcus faecalis 10795 EFEnterococcus faecalis 14104 EF Enterococcus faecalis 16481 EFEnterococcus faecalis 18217 EF Enterococcus faecalis 22442 EFEnterococcus faecalis 25726 EF Enterococcus faecalis 26143 EFEnterococcus faecalis 28131 EF Enterococcus faecalis 29765 EFEnterococcus faecalis 30279 EF Enterococcus faecalis 31234 EFEnterococcus faecalis 31673 EF Enterococcus faecalis 115 EFMEnterococcus faecium 227 EFM Enterococcus faecium 414 EFM Enterococcusfaecium 712 EFM Enterococcus faecium 870 EFM Enterococcus faecium 911EFM Enterococcus faecium 2356 EFM Enterococcus faecium 2364 EFMEnterococcus faecium 2762 EFM Enterococcus faecium 3062 EFM Enterococcusfaecium 4464 EFM Enterococcus faecium 4473 EFM Enterococcus faecium 4653EFM Enterococcus faecium 4679 EFM Enterococcus faecium 6803 EFMEnterococcus faecium 6836 EFM Enterococcus faecium 8280 EFM Enterococcusfaecium 8702 EFM Enterococcus faecium 9855 EFM Enterococcus faecium10766 EFM Enterococcus faecium 12799 EFM Enterococcus faecium 13556 EFMEnterococcus faecium 13783 EFM Enterococcus faecium 14687 EFMEnterococcus faecium 15268 EFM Enterococcus faecium 15525 EFMEnterococcus faecium 15538 EFM Enterococcus faecium 18102 EFMEnterococcus faecium 18306 EFM Enterococcus faecium 19967 EFMEnterococcus faecium 22428 EFM Enterococcus faecium 23482 EFMEnterococcus faecium 29658 EFM Enterococcus faecium 597 EC Escherichiacoli 847 EC Escherichia coli 1451 EC Escherichia coli 8682 ECEscherichia coli 11199 EC Escherichia coli 12583 EC Escherichia coli12792 EC Escherichia coli 13265 EC Escherichia coli 14594 EC Escherichiacoli 22148 EC Escherichia coli 29743 EC Escherichia coli 30426 ECEscherichia coli 470 BSA Group A Streptococcus 2965 BSA Group AStreptococcus 3112 BSA Group A Streptococcus 3637 BSA Group AStreptococcus 4393 BSA Group A Streptococcus 4546 BSA Group AStreptococcus 4615 BSA Group A Streptococcus 5848 BSA Group AStreptococcus 6194 BSA Group A Streptococcus 8816 BSA Group AStreptococcus 11814 BSA Group A Streptococcus 16977 BSA Group AStreptococcus 18083 BSA Group A Streptococcus 18821 BSA Group AStreptococcus 25178 BSA Group A Streptococcus 30704 BSA Group AStreptococcus 12 BSB Group B Streptococcus 10366 BSB Group BStreptococcus 10611 BSB Group B Streptococcus 16786 BSB Group BStreptococcus 18833 BSB Group B Streptococcus 30225 BSB Group BStreptococcus 10422 BSC Group C Streptococcus 14209 BSC Group CStreptococcus 29732 BSC Group C Streptococcus 8544 BSG Group GStreptococcus 18086 BSG Group G Streptococcus 29815 BSG Group GStreptococcus 147 HI Haemophilus influenzae 180 HI Haemophilusinfluenzae 934 HI Haemophilus influenzae 970 HI Haemophilus influenzae1298 HI Haemophilus influenzae 1819 HI Haemophilus influenzae 1915 HIHaemophilus influenzae 2000 HI Haemophilus influenzae 2562 HIHaemophilus influenzae 2821 HI Haemophilus influenzae 3133 HIHaemophilus influenzae 3140 HI Haemophilus influenzae 3497 HIHaemophilus influenzae 3508 HI Haemophilus influenzae 3535 HIHaemophilus influenzae 4082 HI Haemophilus influenzae 4108 HIHaemophilus influenzae 4422 HI Haemophilus influenzae 4868 HIHaemophilus influenzae 4872 HI Haemophilus influenzae 5858 HIHaemophilus influenzae 6258 HI Haemophilus influenzae 6875 HIHaemophilus influenzae 7063 HI Haemophilus influenzae 7600 HIHaemophilus influenzae 8465 HI Haemophilus influenzae 10280 HIHaemophilus influenzae 10732 HI Haemophilus influenzae 10850 HIHaemophilus influenzae 11366 HI Haemophilus influenzae 11716 HIHaemophilus influenzae 11724 HI Haemophilus influenzae 11908 HIHaemophilus influenzae 12093 HI Haemophilus influenzae 12107 HIHaemophilus influenzae 13424 HI Haemophilus influenzae 13439 HIHaemophilus influenzae 13672 HI Haemophilus influenzae 13687 HIHaemophilus influenzae 13792 HI Haemophilus influenzae 13793 HIHaemophilus influenzae 14440 HI Haemophilus influenzae 15351 HIHaemophilus influenzae 15356 HI Haemophilus influenzae 15678 HIHaemophilus influenzae 15800 HI Haemophilus influenzae 17841 HIHaemophilus influenzae 18614 HI Haemophilus influenzae 25195 HIHaemophilus influenzae 27021 HI Haemophilus influenzae 28326 HIHaemophilus influenzae 28332 HI Haemophilus influenzae 29918 HIHaemophilus influenzae 29923 HI Haemophilus influenzae 31911 HIHaemophilus influenzae 428 KPN Klebsiella pneumoniae 791 KPN Klebsiellapneumoniae 836 KPN Klebsiella pneumoniae 1422 KPN Klebsiella pneumoniae1674 KPN Klebsiella pneumoniae 1883 KPN Klebsiella pneumoniae 6486 KPNKlebsiella pneumoniae 8789 KPN Klebsiella pneumoniae 10705 KPNKlebsiella pneumoniae 11123 KPN Klebsiella pneumoniae 28148 KPNKlebsiella pneumoniae 29432 KPN Klebsiella pneumoniae 937 MCAT Moraxellacatarrhalis 1290 MCAT Moraxella catarrhalis 1830 MCAT Moraxellacatarrhalis 1903 MCAT Moraxella catarrhalis 4346 MCAT Moraxellacatarrhalis 4880 MCAT Moraxella catarrhalis 6241 MCAT Moraxellacatarrhalis 6551 MCAT Moraxella catarrhalis 7074 MCAT Moraxellacatarrhalis 7259 MCAT Moraxella catarrhalis 7544 MCAT Moraxellacatarrhalis 8142 MCAT Moraxella catarrhalis 8451 MCAT Moraxellacatarrhalis 9246 MCAT Moraxella catarrhalis 9996 MCAT Moraxellacatarrhalis 12158 MCAT Moraxella catarrhalis 13443 MCAT Moraxellacatarrhalis 13692 MCAT Moraxella catarrhalis 13817 MCAT Moraxellacatarrhalis 14431 MCAT Moraxella catarrhalis 14762 MCAT Moraxellacatarrhalis 14842 MCAT Moraxella catarrhalis 15361 MCAT Moraxellacatarrhalis 15741 MCAT Moraxella catarrhalis 17843 MCAT Moraxellacatarrhalis 18639 MCAT Moraxella catarrhalis 241 GC Neisseriagonorrhoeae 291 GC Neisseria gonorrhoeae 293 GC Neisseria gonorrhoeae344 GC Neisseria gonorrhoeae 451 GC Neisseria gonorrhoeae 474 GCNeisseria gonorrhoeae 491 GC Neisseria gonorrhoeae 493 GC Neisseriagonorrhoeae 503 GC Neisseria gonorrhoeae 521 GC Neisseria gonorrhoeae552 GC Neisseria gonorrhoeae 573 GC Neisseria gonorrhoeae 592 GCNeisseria gonorrhoeae 25 NM Neisseria meningitidis 813 NM Neisseriameningitidis 1725 NM Neisseria meningitidis 2747 NM Neisseriameningitidis 3201 NM Neisseria meningitidis 3335 NM Neisseriameningitidis 7053 NM Neisseria meningitidis 9407 NM Neisseriameningitidis 10447 NM Neisseria meningitidis 12685 NM Neisseriameningitidis 12841 NM Neisseria meningitidis 14038 NM Neisseriameningitidis 1127 PM Proteus mirabilis 3049 PM Proteus mirabilis 4471 PMProteus mirabilis 8793 PM Proteus mirabilis 10702 PM Proteus mirabilis11218 PM Proteus mirabilis 14662 PM Proteus mirabilis 17072 PM Proteusmirabilis 19059 PM Proteus mirabilis 23367 PM Proteus mirabilis 29819 PMProteus mirabilis 31419 PM Proteus mirabilis 1881 PSA Pseudomonasaeruginosa 5061 PSA Pseudomonas aeruginosa 7909 PSA Pseudomonasaeruginosa 8713 PSA Pseudomonas aeruginosa 14318 PSA Pseudomonasaeruginosa 14772 PSA Pseudomonas aeruginosa 15512 PSA Pseudomonasaeruginosa 17093 PSA Pseudomonas aeruginosa 17802 PSA Pseudomonasaeruginosa 19661 PSA Pseudomonas aeruginosa 29967 PSA Pseudomonasaeruginosa 31539 PSA Pseudomonas aeruginosa 82 SA Staphylococcus aureus99 SA Staphylococcus aureus 138 SA Staphylococcus aureus 139 SAStaphylococcus aureus 140 SA Staphylococcus aureus 141 SA Staphylococcusaureus 142 SA Staphylococcus aureus 272 SA Staphylococcus aureus 287 SAStaphylococcus aureus 354 SA Staphylococcus aureus 382 SA Staphylococcusaureus 1112 SA Staphylococcus aureus 1687 SA Staphylococcus aureus 1848SA Staphylococcus aureus 2031 SA Staphylococcus aureus 2159 SAStaphylococcus aureus 2645 SA Staphylococcus aureus 3256 SAStaphylococcus aureus 3276 SA Staphylococcus aureus 4044 SAStaphylococcus aureus 4214 SA Staphylococcus aureus 4217 SAStaphylococcus aureus 4220 SA Staphylococcus aureus 4231 SAStaphylococcus aureus 4240 SA Staphylococcus aureus 4262 SAStaphylococcus aureus 4370 SA Staphylococcus aureus 4665 SAStaphylococcus aureus 4666 SA Staphylococcus aureus 4667 SAStaphylococcus aureus 5026 SA Staphylococcus aureus 5666 SAStaphylococcus aureus 6792 SA Staphylococcus aureus 7023 SAStaphylococcus aureus 7461 SA Staphylococcus aureus 7899 SAStaphylococcus aureus 7901 SA Staphylococcus aureus 8714 SAStaphylococcus aureus 9374 SA Staphylococcus aureus 9437 SAStaphylococcus aureus 10056 SA Staphylococcus aureus 10110 SAStaphylococcus aureus 11379 SA Staphylococcus aureus 11629 SAStaphylococcus aureus 11659 SA Staphylococcus aureus 12788 SAStaphylococcus aureus 12789 SA Staphylococcus aureus 13043 SAStaphylococcus aureus 13086 SA Staphylococcus aureus 13721 SAStaphylococcus aureus 13742 SA Staphylococcus aureus 13932 SAStaphylococcus aureus 14210 SA Staphylococcus aureus 14384 SAStaphylococcus aureus 15428 SA Staphylococcus aureus 15430 SAStaphylococcus aureus 17721 SA Staphylococcus aureus 18688 SAStaphylococcus aureus 19095 SA Staphylococcus aureus 20195 SAStaphylococcus aureus 22141 SA Staphylococcus aureus 22689 SAStaphylococcus aureus 27398 SA Staphylococcus aureus 29048 SAStaphylococcus aureus 29051 SA Staphylococcus aureus 30491 SAStaphylococcus aureus 30538 SA Staphylococcus aureus 25 SEPIStaphylococcus epidermidis 53 SEPI Staphylococcus epidermidis 385 SEPIStaphylococcus epidermidis 398 SEPI Staphylococcus epidermidis 701 SEPIStaphylococcus epidermidis 713 SEPI Staphylococcus epidermidis 1381 SEPIStaphylococcus epidermidis 2174 SEPI Staphylococcus epidermidis 2286SEPI Staphylococcus epidermidis 2969 SEPI Staphylococcus epidermidis3417 SEPI Staphylococcus epidermidis 3447 SEPI Staphylococcusepidermidis 4753 SEPI Staphylococcus epidermidis 7241 SEPIStaphylococcus epidermidis 9366 SEPI Staphylococcus epidermidis 10665SEPI Staphylococcus epidermidis 11792 SEPI Staphylococcus epidermidis12311 SEPI Staphylococcus epidermidis 13036 SEPI Staphylococcusepidermidis 13227 SEPI Staphylococcus epidermidis 13243 SEPIStaphylococcus epidermidis 13621 SEPI Staphylococcus epidermidis 13638SEPI Staphylococcus epidermidis 13800 SEPI Staphylococcus epidermidis14078 SEPI Staphylococcus epidermidis 14392 SEPI Staphylococcusepidermidis 15007 SEPI Staphylococcus epidermidis 16733 SEPIStaphylococcus epidermidis 18871 SEPI Staphylococcus epidermidis 23285SEPI Staphylococcus epidermidis 27805 SEPI Staphylococcus epidermidis29679 SEPI Staphylococcus epidermidis 29985 SEPI Staphylococcusepidermidis 30259 SEPI Staphylococcus epidermidis 31444 SEPIStaphylococcus epidermidis 268 SPN Streptococcus pneumoniae 1264 SPNStreptococcus pneumoniae 2482 SPN Streptococcus pneumoniae 2653 SPNStreptococcus pneumoniae 2994 SPN Streptococcus pneumoniae 3123 SPNStreptococcus pneumoniae 3124 SPN Streptococcus pneumoniae 4336 SPNStreptococcus pneumoniae 4858 SPN Streptococcus pneumoniae 5606 SPNStreptococcus pneumoniae 5881 SPN Streptococcus pneumoniae 5897 SPNStreptococcus pneumoniae 5900 SPN Streptococcus pneumoniae 6051 SPNStreptococcus pneumoniae 6216 SPN Streptococcus pneumoniae 6556 SPNStreptococcus pneumoniae 7270 SPN Streptococcus pneumoniae 7584 SPNStreptococcus pneumoniae 8479 SPN Streptococcus pneumoniae 8501 SPNStreptococcus pneumoniae 9256 SPN Streptococcus pneumoniae 9257 SPNStreptococcus pneumoniae 10246 SPN Streptococcus pneumoniae 10467 SPNStreptococcus pneumoniae 10886 SPN Streptococcus pneumoniae 11217 SPNStreptococcus pneumoniae 11228 SPN Streptococcus pneumoniae 11238 SPNStreptococcus pneumoniae 11757 SPN Streptococcus pneumoniae 11768 SPNStreptococcus pneumoniae 12121 SPN Streptococcus pneumoniae 12124 SPNStreptococcus pneumoniae 12149 SPN Streptococcus pneumoniae 12767 SPNStreptococcus pneumoniae 12988 SPN Streptococcus pneumoniae 13321 SPNStreptococcus pneumoniae 13393 SPN Streptococcus pneumoniae 13521 SPNStreptococcus pneumoniae 13544 SPN Streptococcus pneumoniae 13700 SPNStreptococcus pneumoniae 13704 SPN Streptococcus pneumoniae 13822 SPNStreptococcus pneumoniae 13838 SPN Streptococcus pneumoniae 14131 SPNStreptococcus pneumoniae 14413 SPN Streptococcus pneumoniae 14744 SPNStreptococcus pneumoniae 14808 SPN Streptococcus pneumoniae 14827 SPNStreptococcus pneumoniae 14835 SPN Streptococcus pneumoniae 14836 SPNStreptococcus pneumoniae 15832 SPN Streptococcus pneumoniae 17336 SPNStreptococcus pneumoniae 17343 SPN Streptococcus pneumoniae 17349 SPNStreptococcus pneumoniae 17735 SPN Streptococcus pneumoniae 18060 SPNStreptococcus pneumoniae 18567 SPN Streptococcus pneumoniae 18595 SPNStreptococcus pneumoniae 19082 SPN Streptococcus pneumoniae 19826 SPNStreptococcus pneumoniae 22174 SPN Streptococcus pneumoniae 22175 SPNStreptococcus pneumoniae 27003 SPN Streptococcus pneumoniae 28310 SPNStreptococcus pneumoniae 28312 SPN Streptococcus pneumoniae 29890 SPNStreptococcus pneumoniae 29910 SPN Streptococcus pneumoniae

What is claimed is:
 1. A solid Form I of the compound of formula (I):


2. The solid Form I of claim 1, which is characterized by an X-raypowder diffraction pattern (XPRD) comprising at least three approximatepeak positions (degrees 2 θ±0.2) when measured using Cu Kα radiation,selected from the group consisting of 9.3, 11.7, 12.1, 12.4, 14.5, 15.9,16.3, 16.6, 18.5, 19.4, 21.5, 22.3, 22.8, 23.8, 24.5, 25.7, 28.1, 28.4,30.3, and 33.4, when the XPRD is collected from about 5 to about 38degrees 2 θ.
 3. The solid Form I of claim 1, which is characterized byan X-ray powder diffraction pattern (XPRD) comprising at least threeapproximate peak positions (degrees 2 θ±0.2) when measured using Cu Kαradiation, selected from the group consisting of 9.3, 16.6, 18.5, 19.4,21.5, and 25.7, when the XPRD is collected from about 5 to about 38degrees 2 θ.
 4. The solid Form I of claim 3, characterized by an X-raypowder diffraction pattern, as measured using Cu Kα radiation,substantially similar to FIG.
 1. 5. The solid Form I of claim 4, furthercharacterized by an endothermic peak having an onset temperature atabout 318° C. as measured by differential scanning calorimetry in whichthe temperature is scanned at about 10° C. per minute.
 6. A method forpreparing crystal Form I of the compound of formula (I) according toclaim 1 comprising suspending a solid material of the free base in asolvent system comprising an alcohol and an ether and isolating thesolid.
 7. A hydrochloric acid salt of the compound of formula (I):


8. The hydrochloric acid salt of claim 7, wherein said salt is Form IIsolid form.
 9. The hydrochloric acid salt of claim 8, wherein said FormII solid form is characterized by an X-ray powder diffraction pattern(XPRD) comprising at least three approximate peak positions (degrees 2θ±0.2) when measured using Cu Kα radiation, selected from the groupconsisting of 6.7, 9.2, 16.7, 18.6, 19.5, 20.5, 25.6, and 27.5, when theXPRD is collected from about 5 to about 38 degrees 2 θ.
 10. Thehydrochloric acid salt of claim 8, wherein said Form II solid form ischaracterized by an X-ray powder diffraction pattern, as measured usingCu Kα radiation, substantially similar to FIG.
 4. 11. The hydrochloricacid salt of claim 9, wherein said Form II solid form is furthercharacterized by an endothermic peak having an onset temperature atabout 252° C. as measured by differential scanning calorimetry in whichthe temperature is scanned at about 10° C. per minute.
 12. A method forpreparing solid Form II of the hydrochloride salt of the compound offormula (I) according to claim 8 comprising suspending a free base ofthe 6-fluorobenzimidazolyl urea compound in an acidic solvent mixturecomprising one or more ethereal solvents and water.
 13. An amorphousForm III of the 6-fluorobenzimidazolyl urea compound of formula I:


14. The amorphous Form III of the fluorobenzimidazolyl urea compoundaccording to claim 13, which is characterized by an X-ray powderdiffraction pattern (XPRD) using Cu Kα radiation, characterized by abroad halo with no discernable diffraction peak.
 15. A method forpreparing amorphous Form III of the 6-fluorobenzimidazolyl urea compoundaccording to claim 13 comprising lyophilizing, spray drying, drumdrying, or pulse conversion drying a solution of the6-fluorobenzimidazolyl urea compound.
 16. An amorphous Form IV of themesylate salt of the 6-fluorobenzimidazolyl urea compound of formula I:


17. The amorphous Form IV of the mesylate salt of the6-fluorobenzimidazolyl urea compound according to claim 16, which ischaracterized by an X-ray powder diffraction pattern (XPRD) using Cu Kαradiation, characterized by a broad halo with no discernable diffractionpeak.
 18. The hydrochloric acid salt of claim 8, wherein said Form IIsolid form is stable for at least one month at 40° C. with relativehumidity of up to 75%.
 19. The solid Form I of claim 2, wherein saidsolid is stable for at least one month at 40° C. with relative humidityof up to 75%.
 20. A pharmaceutical composition comprising the compoundaccording to claim 1 and a pharmaceutically acceptable carrier,adjuvant, or vehicle.
 21. A method for treating a bacterial infection ina patient, wherein the bacterial infection is characterized by thepresence of one or more of Mycobacterium tuberculosis, Streptococcuspneumoniae, Staphylococcus epidermidis, Enterococcus faecalis,Staphylococcus aureus, Clostridium difficile, Moraxella catarrhalis,Neisseria gonorrhoeae, Neisseria meningitidis, Mycobacterium aviumcomplex, Mycobacterium abscessus, Mycobacterium kansasii, Mycobacteriumulcerans, Chlamydophila pneumoniae, Chlamydia trachomatis, Haemophilusinfluenzae, Streptococcus pyogenes or β-haemolytic streptococci,comprising administering to said patient a pharmaceutical compositionaccording to claim
 20. 22. The method according to claim 21, wherein thebacterial infection is selected from one or more of the following: upperrespiratory infections, lower respiratory infections, ear infections,pleuropulmonary and bronchial infections, complicated urinary tractinfections, uncomplicated urinary tract infections, intra-abdominalinfections, cardiovascular infections, a blood stream infection, sepsis,bacteremia, CNS infections, skin and soft tissue infections, GIinfections, bone and joint infections, genital infections, eyeinfections, or granulomatous infections, uncomplicated skin and skinstructure infections (uSSSI), complicated skin and skin structureinfections (cSSSI), catheter infections, pharyngitis, sinusitis, otitisexterna, otitis media, bronchitis, empyema, pneumonia,community-acquired bacterial pneumoniae (CABP), hospital-acquiredpneumonia (HAP), hospital-acquired bacterial pneumonia,ventilator-associated pneumonia (VAP), diabetic foot infections,vancomycin resistant enterococci infections, cystitis andpyelonephritis, renal calculi, prostatitis, peritonitis, complicatedintra-abdominal infections (cIAI) and other inter-abdominal infections,dialysis-associated peritonitis, visceral abscesses, endocarditis,myocarditis, pericarditis, transfusion-associated sepsis, meningitis,encephalitis, brain abscess, osteomyelitis, arthritis, genital ulcers,urethritis, vaginitis, cervicitis, gingivitis, conjunctivitis,keratitis, endophthalmitisa, an infection in cystic fibrosis patients oran infection of febrile neutropenic patients.
 23. The method accordingto claim 22, wherein the bacterial infection is selected from one ormore of the following: community-acquired bacterial pneumoniae (CABP),hospital-acquired pneumonia (HAP), hospital-acquired bacterialpneumonia, ventilator-associated pneumonia (VAP), bacteremia, diabeticfoot infections, catheter infections, uncomplicated skin and skinstructure infections (uSSSI), complicated skin and skin structureinfections (cSSSI), vancomycin resistant enterococci infections orosteomyelitis.